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Structural and Functional Studies on IroB 
Daniel Foshag 
Bacterial iron acquisition by the means of enterobactin (ENT) is constrained in mammalian 
hosts due to ENT-binding proteins such as siderocalin and serum albumin. To evade 
sequestration by these proteins, ENT can be modified by the C-glycosyltransferase IroB, 
which is located in the iroA locus of Salmonella and certain extraintestinal E. coli strains 
such as uropathogenic E. coli CFT073. The glycosylation of ENT has been reported to be a 
bacterial evasion mechanism to restore the iron scavenging ability of ENT in the presence 
of mammalian ENT-binding proteins by the installation of a steric impediment.  
The C-glycosyltransferase IroB catalyses the transfer of a glucose moiety to the DHB 
subunit of ENT under formation of a C-C bond between the anomeric C1 of the glucose 
moiety and the C5 of the 2,3-DHB subunit of ENT. The formation of mono-, di- and 
triglycosylated Ent (MGE/DGE/TGE) products where observed in vitro. The formation of 
a C-C bond is remarkable because of its chemical stability and resilience against enzymatic 
degradation.  
In this M.Sc. thesis, we initially identified the iroB gene product in the iroA-harbouring 
E. coli strain Nissle 1917 on transcriptional and translational level and expressed and 
purified IroB recombinant. Then, we investigated the mechanism of the C-C bond 
formation catalysed by IroB in vitro. Based on the hypothesis that deprotonation of the 
catechol 2-hydroxyl renders the catechol C5 para to the 2-hydroxyl nucleophilic, the C-C 
bond would then be formed in a general SN2 reaction between the attacking nucleophile 
and the anomeric carbon of glucose, which is further facilitated by the excellent phosphate 
leaving group of the UDP-glucose donor. By the means of homology modelling and 
superposition strategies, we were able to identify the binding sites of the glycosyl donor 
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UDP-glucose and the glycosyl acceptor ENT and to locate residues that could potentially 
act as base catalysts to increase the phenolate anionic character of the 2,3-DHB subunit 
during catalysis.  
We established an activity assay for IroB, separated products arising from IroB activity by 
reversed phase chromatography and compared so the activity of wild-type IroB and several 
variants. Additionally, all variants were characterized biophysically, mainly to confirm that 
the structural integrity was not impaired by mutations. Ultimately, our results enable us to 
propose a mechanism for C-glycosylation of IroB that is consistent with other 
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1 General introduction 
Iron is an essential nutrient for most organisms, representing an important cofactor 
needed by approximately one-quarter to one-third of all proteins including those involved 
in primary and secondary metabolism (1, 2). These so-called metalloproteins can bind 
iron either directly using amino acid side chains, but mostly binding is mediated by heme 
groups or iron-sulphur clusters (2). Metalloproteins are an integral part of metabolic 
processes such as photosynthesis, respiration and nitrogen fixation (3). The reversible 
redox pair Fe
2+
 (ferrous iron) and its oxidized form Fe
3+
 (ferric iron) are the 
physiologically relevant iron sources. They are involved in broad spectrum of redox 
reactions, mediate electron chain transfer and serve as cofactor for structural and 
functional integrity of proteins. The bacterial uptake of iron is limited to these two 
physiologically relevant forms (1, 3, 4).  
The reduced form Fe
2+
 is soluble in aqueous solution and thus readily available to 
bacterial metal transport systems. However, in bacterial habitats, Fe
2+
 is mostly oxidized 
to Fe
3+
 by molecular oxygen or enzymatic processes in mammalian hosts and Fe
3+
 is 
mostly insoluble (5, 6). The hard Lewis acid Fe
3+
 forms preferably adducts with hard 
Lewis bases such as water or hydroxides and is hexacoordinated at pH <1 by six water 
molecules. However, with increasing pH, the ferric coordinating water molecules 
eventually ionize to form a ferric-hydroxide complex. The ferric-hydroxide complex is 
prone to undergo a process named olation and oxolation, where oxygen and hydroxides 
act as bridging molecules and induce the formation higher order insoluble polymers 
between different ferric-hydroxide complexes (7). Ultimately, these processes lead to 
formation of ferric oxide hydrate complexes (Fe2O2 x nH2O). The solubility of ferric-
2 
 
oxide hydrate complexes is limited to a concentration of 10
-18 
M in aqueous solution at 
neutral pH. Thus, even though iron is one of the most abundant elements in the terrestrial 
environment, its availability is highly constrained by its low solubility and is far from the 
concentration needed by bacterial cells to maintain metabolism (the threshold metabolite 
concentration within the cells is in the micro molar range (6)). In mammalian hosts, the 
habitat of important pathogens, the availability of iron is even more limited due to 
sequestration of free Fe
3+
 to storage and transport proteins such as ferritin and transferrin. 
Iron chelation mechanisms in mammals result in a free serum iron(III) concentration of 
about 10
-24
 M. For this reason, serum is considered bacteriostatic (8-10).    
In order to overcome these limitations and satisfy their need for iron, bacteria evolved 
different iron acquisition strategies. Evolution has led to two different strategies: direct 
and indirect uptake of iron. The first strategy incorporates direct uptake from iron sources 
such as the mammalian iron binding protein transferrin. One species that employs this 
strategy is the Gram-negative bacterium Neisseria gonorrhoeae that harbours the TbpA 
and the co-receptor TbpB. The Tbp-system allows binding of human transferrin and 
extraction of the iron(III) bound to transferrin. The crystal structure of receptor and co-
receptor in complex with human transferrin was solved recently (11).  The disadvantage 
of this strategy is that a specific receptor for each iron source is needed – in such a way 
the TbpA/B system is restricted to transferrin. The more widespread indirect uptake will 




1.1 Indirect uptake of iron 
In principle, the indirect uptake strategy is quite diverse in its appearance. Some Gram-
negative bacteria, for example, harbour an iron-acquisition system known as has, which 
is capable of exploiting different heme sources through the use of secreted hemophores 
that extract iron from heme (12, 13). However, this type of iron acquisition is quite 
similar to the direct uptake strategy and possesses similar disadvantages – it involves 
specialized molecules highly specific for a single iron source (e.g., heme)  and is 
therefore limited to particular compartments where these sources are available (1). 
The most distributed, and possibly the most successful, strategy is based on highly 
efficient iron-chelating molecules called siderophores (greek for: "iron carrier") (14). 
These small (usually <1 kDa) molecules demonstrate a high affinity for ferric iron and 
are capable to “steal” iron from almost every source. Siderophores can by divided into 
three main categories on the basis of the functional group that is involved in Fe
3+
 
coordination (15).  
 
1.2 Siderophores  
There are three major functional groups found in siderophores responsible for 
coordination of iron(III): catecholate (includes catecholate and phenolate (aka “aryl 
caps”), hydroxamate, and carboxylate (Figure 1) (1, 15). As mentioned elsewhere, Fe3+ is 
considered a hard Lewis acid that forms adducts with hard Lewis bases such as oxygens, 
water molecules or hydroxides in solution, preferably in a hexacoordinated manner with 
octahedral geometry. The functional groups in siderophores (catechol, carboxylate and 
hydroxamate) described to date all possess strong oxygen donor to coordinate iron(III). 
4 
 
On the contrary, for coordination of the intermediate Lewis acid Fe
2+
, donor atoms like 
nitrogen or sulfur are preferred (16). 
 
   
Figure 1: various types of siderophores with different functional groups and the corresponding 
natural producer. They are classified by the chemical nature of their functional group. The catechol 
group is highlighted is red, the phenolate group in orange, hydroxamate in yellow and carboxylate 
group in green (1).   
 
The hexacoordination with octahedral geometry is thermodynamically very stable and is 
imitated by iron chelators. The functional groups of siderophores, for instance, generally 
supply six oxygen donors to coordinate  Fe
3+
 in a highly stable hexacoordinated state that 
can be found for ENT (six hydroxyl groups) or desferrioxamine (three hydroxamate 
groups, each with two oxygen donors). Siderophores providing six donor atoms to form 
complexes with a 1:1 stochiometry, whereas if less than six donors are available (e.g., 
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pyochelin from Pseudomonas aeroginosa), then complexes with higher stoichiometry 
may be formed or, alternatively, vacancies may be occupied by water molecules (17).  
The efficiency of catechol siderophores is also dependent on the protonation state of their 
coordinating hydroxyl groups. Therefore, the affinity for Fe
3+
 is pH dependent and the 
physiological context must be considered. Many fungal species, for instance, live under 
acidic conditions, where the catechol hydroxyl groups would be fully protonated, making 
this type of siderophore less efficient under the acidic conditions of such a habitat. 
Therefore organisms living under these conditions prefer siderophores of the carboxylate 
type, with pKa values of coordinating groups ranging between 3.5-5.0. Thus, 
carboyxylate type siderophores are more effective under acidic conditions (1, 18). 
However, the strongest siderophore under physiological conditions is known to be the 
catecholate siderophore enterobactin (ENT), which is described in the following Section.         
 
1.2.1 The catecholate siderophore ENT 
The catecholate siderophore ENT was first isolated from Escherichia coli and Salmonella 
typhimurium. ENT features threefold symmetry with three functional catecholate groups 
connected via an amide linkage to a trilactone macrocycle backbone (19) as shown in 
Figure 2. 
As discussed briefly in the previous Section, ENT is an extremely strong iron chelator 
with an estimated equilibrium dissociation constant for Fe
3+
 to ENT of KD ~ 10
-50 
M (20); 
however, this estimated value refers to the rather hypothetical protonation state, where all 
six hydroxyl groups of the three catechol subunits are deprotonated. Since the backbone 
is easily hydrolyzed and thus unstable at high pH at which all hydroxyls could be 
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deprotonated, this value does not reflect physiological conditions. The experimentally 
determined equilibrium dissociation constant, however, remains impressive: the KD for 
Fe
3+
 binding at pH 7.4 was determined to be 10
-35.5
 M, based on a competition assay with 
EDTA (19). The high affinity of Fe
3+
 to ENT is largely due to the fact that the metal ion 
is coordinated in the thermodynamically favoured hexacoordination sphere with 
octahedral geometry, as shown in Figure 2, lower panel right (21).  
 
 
Figure 2: Structural representation of ENT (upper left). ENT possesses three catecholate groups 
connected via an amide linkage to a trilactone macrocycle backbone. The conformation of the 
catecholate group is charge-driven (upper right). Spacefilling representation (red oxygen, blue 
nitrogen, white hydrogen, grey carbon, green ferric iron) of ENT can be seen in the lower figure. The 
figure (lower left) shows the space filling representation of the protonated and uncomplexed ENT. 
Upon deprotonation, the functional hydroxyl groups point to the center and coordinates the metal 
ion in a hexacoordinated state with octahedral geometry (21). 
 
Not only the equilibrium dissociation constant for iron(III), but also the conformation of 
ENT is charge-driven and depends upon the pH.  The ortho-hydroxyl groups (C2) with 
respect to the amide linked C1 exhibits a pKa of 6.5 to 8 and the meta-hydroxyl group 
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(C3) possesses a pKa of 11.5.  At pH values below its pKa, the ortho-hydroxyl group is 
bonded to the amide oxygen and the hydroxyl groups are pointing away from the center. 
Upon deprotonation or metal binding the ortho-hydroxyl group changes to the trans 
position, whereas the ortho-hydroxyl group is hydrogen bonded to the nitrogen of the 
amide linkage (1, 21, 22). 
 
1.2.2 Biosynthesis of ENT 
Proteins involved in the biosynthesis, export and reuptake of ENT are clustered on the 
ent/fep locus (Figure 3), which can be found in a large number of Gram-negative and 
Gram-positive bacteria. The gene expression for iron acquisition must be tightly 
regulated to avoid the accumulation of free iron, which can be toxic for the cell, but also 
to maintain an intracellular iron concentration at approximately 10
-6 
M for metabolic 
processes (6, 15). To achieve a tight regulation of the expression of genes involved in 
iron acquisition by ENT, bacteria have evolved two different transcription factors. In 
Gram-positive bacteria iron acquisition is controlled by DtxR (diphtheria toxin regulator) 
and in Gram negative (enteric bacteria) the control is accomplished by Fur (Ferric Uptake 
Regulator). Interestingly, the DtxR is found often in Gram-negative bacteria in addition 
to Fur and controls manganese transport (23).    
Even though these regulators show low sequence identity, structural features are well 
conserved. Both regulators possess a structural binding site for zinc that mediates 
dimerization and a regulatory binding site for Fe
2+
, which enables Fur to bind to its DNA 
recognition site (24). The DNA recognition site is known as the Fur box, and features the 
following inverted repeat consensus sequence: 5’-GATAATGATAATCATTATC-3’ 
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(23). The ent/fep locus is negatively regulated by Fur depending on the concentration – 
expression is repressed when Fe
2+
 is bound to the regulatory binding site on Fur and 
derepressed under low iron availability due to Fe
2+
 dissociation from Fur (24, 25). 
Proteins involved in biosynthesis and uptake of iron are almost exclusively regulated at 
the transcriptional level (26).  
 
 
Figure 3: Fep/Ent gene cluster regulated by Fur (ferric uptake repressor) (19) 
 
The ent/fep cluster encodes for proteins EntA-F, EntS, FepA-G and Fes. EntCBA (Figure 
3) are involved in the synthesis of the functional DHB subunit of ENT and EntDEF 
assemble three DHB subunits and three L-serines to the final ENT molecule. EntS is 
responsible for secretion of ENT. The proteins FepAB and FepCDG import holo-ENT, 
where FepAB mediate transport through the outer membrane and FepCDG is the inner 
membrane permease complex. Finally, Fes is required for the release of Fe
3+
 from its 
ligand following import to the cytoplasm. The ENT biosynthetic and synthetic pathway is 










































Figure 4: Biosynthetic and synthetic pathway for ENT. EntCBA are catalysing the conversion of 
chorismate to the final functional group 2,3-dihydroxybenzoic acid (DHB). EntDEF assembles the 
final ENT molecule using three L-serine molecules and connecting it via an amide linkage to three 
DHB subunit groups and enzymatic tethering of the three DHB-S units.   
 
The biosynthesis of ENT can be divided in two modules, where the DHB module 
involves the activities of EntCBA (DHB subunit) and the non-ribosomal peptide 
synthesis (NRPS) module that involves the activities of EntDEF (assembly of three DHB 
subunit and three L-serine).  The DHB module starts from an offshoot of the aromatic 
amino acid pathway. Firstly, chorismic acid is converted to isochorismate in the presence 
of magnesium by the isochorismate synthase EntC. In the next step, the isochorismatase 
activity of EntB converts isochorismate into 2, 3-dihydro-2,3-dihydroxybenzoate under 
removal of pyruvate. This intermediate is then oxidized to 2,3-dihydroxybenzoic acid in 
the presence of cofactor NAD
+ 
 by EntA (21). 
EntB is bifunctional protein that possesses an N-terminal isochorismate lyase domain 
involved in DHB biosynthesis and a C-terminal ArCP (aryl carrier protein domain) that 
also plays an essential role in the NRPS module of ENT assembly. During NRPS, the 
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EntB ArCP domain is phosphopantetheinylated by EntD to produce a holo-ArCP domain 
that facilitates transfer of adenylation-activated 2, 3-DHB onto holo-EntB by EntE (27).  
EntF is a multidomain (C-A-PCP-TE) protein and the central enzyme for final assembly 
of ENT in cooperation EntB. The A (adenylation) domain of EntF activates L-serine also 
by adenylation, which is then covalently attached to the PCP (peptide carrier protein) 
domain of EntF. The C (condensation) domain of EntF catalyses the formation of an 
amide linkage between L-serine using holo-EntB as the DHB donor. The DHB-serine 
product is then transferred to the TE domain of EntF, which makes the PCP domain 
available for another round to condense DHB and serine.  In the course of this ‘assembly 
line’ process, three DHB-Ser are formed, transferred to the TE (termination) domain of 
EntF and covalently tethered to produce the final ENT molecule (19, 21, 27, 28).  
   
1.3 Mammalian Defense Mechanisms against Bacterial Iron Acquisition 
As described elsewhere, iron is extremely important in a variety of metabolic processes 
of bacteria, including pathogens, but its availability in mammalian host is limited due to 
sequestration by iron binding proteins such as transferrin or ferritin or prosthetic heme 
groups (6, 12, 13, 29). By the means of sequestration by transferrin, mammals limit the 
available free iron to a bacteriostatic concentration of 10
-24 
M in serum (30). However, by 
secretion of siderophores, many bacteria possess highly efficient molecular mechanisms 
to extract iron from different sources including transferrin or ferritin, thus enabling them 
to overcome limitations imposed by these mammalian iron binding proteins (30). In order 
to control siderophore-based iron acquisition, the innate immune system of mammals also 
directly interferes with this mode of iron-acquisition through the use of proteins known as 
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lipocalins (31). A lipocalin that has been demonstrated to interfere directly with ENT-
mediated iron acquisition is NGAL (neutrophil gelatinase-associated lipocalin) (32); the 
surface representation is shown in Figure 5.  It is secreted upon induction of an 
inflammation response by neutrophil granulocytes (white blood cells) and has been 
shown to bind holo-ENT (i.e., ferric ENT) and also other siderophores with high affinity 
(KD = 0.4 ± 0.1 nM) (31). 
.  
Figure 5: Siderocalin (surface representation), indicated with numerals 1,2 and 3 are the binding 
pockets that accommodate the DHB subunit upon binding of FeENT (left) and FeENT bound 
siderocalin (right) (31). 
 
Lipocalins are quite diverse in terms of their sequence, but they share a characteristic 
fold: they possess an eight-stranded antiparallel β-barrel that surrounds a binding pocket 
called calyx; protein-ligand specificity is defined by residues in the calyx (33). 
NGAL features a high specificity for holo-ENT, the calyx is defined by three binding 
pockets (1, 2 and 3; Figure 5) pockets accommodate the catechol subunits of ENT as 
shown in the right panel in Figure 5. In these binding pockets the positively charged 




charge of 0, the FeENT complex however has a charge net charge of -3 (34). Thus, the 
interaction between the residues in the calyx and Fe-loaded ENT is composed of 
electrostatic and cation-π interactions between the catechol group of ENT and the 
positively-charged residues in the binding pocket of NGAL (31). The physiological 
relevance of the NGAL-FeENT interaction has been shown in in vitro and in vivo. For 
instance, NGAL-deficient mice are susceptible to infection by E. coli and growth of E. 
coli is limited in the presence of NGAL (34, 35).    
Since the mammalian innate immune features an excellent countermeasure against ENT- 
based iron acquisition via NGAL, certain pathogens carry an additional “second layer” 
iron acquisition system called iroA. This system depends on the ent/fep system and 
facilitates glycosylation of ENT and additionally provides specialized uptake and 
reuptake systems to restore the iron-scavenging ability of ENT in the presence of 
mammalian NGAL (30, 36).  An essential protein of the iroA system, IroB, is the focus of 
this thesis. 
 
1.4 iroA – a pathogen-associated iron acquisition system 
In addition to sequestration of ENT by NGAL that was described in the previous chapter, 
the efficiency of the ent/fep system in mammalian hosts is also impaired by the 
hydrophobic character of ENT. Its hydrophobicity results in partitioning into lipid 
bilayers (37) and/or association with serum proteins such as albumin that binds 
hydrophobic ligands (38). These factors together limit the bioavailability of Fe-ENT, thus 
affecting iron homeostasis of pathogens in the presence of mammalian host proteins (30).  
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To overcome these limitations, important pathogens such as uropathogenic E. coli 
(CFT073), Salmonella species and certain Klebsiella strains harbor the “second layer” 
iron acquisition system iroA. The iroA locus, comprised of a five-gene cluster that will be 
described in more detail later, allows for glycosylation of ENT and thus alters its physical 
and steric properties (36). In Table 1 the presence of different iron acquisition systems in 
intestinal and extraintestinal E. coli isolates are tabulated, which demonstrates that the 
iroA cluster is exclusively found in extraintestinal isolates. 
 
Table 1: The presence of various iron-acquisition systems in intestinal/extraintestinal E. coli isolates. 
Data taken from (19). 











E. coli      
 Intestinal      
  K-12 + - - + - 
  EPEC E2348/69 + - - + - 
  EAggEC O42 + - + + - 
  EHEC O157:H7 + - + + - 
 Extraintestinal      
  UPEC (CFT073) + + + + + 












While E. coli is a mutualistic organism in the human intestinal tract and thus contributes 
to human health, it can cause infections when present at extraintestinal locations such as 
the urinary tract or in wounds and other tissues. The ability to survive in extraintestinal 
environments depends on several virulence factors, including the ability to scavenge iron 
when competing with the mammalian immune system (39). When comparing iron 
acquisition systems present in intestinal and extraintestinal isolates in Table 1, one might 
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notice that the iroA system is not found in any listed intestinal E. coli isolate, but in every 
extraintestinal isolate. This suggests that the iroA cluster plays a significant role as a 
virulence factor. In fact, this notion is supported by a recent study that identified 
salmochelin and ENT followed by aerobactin in E. coli 83972 (asymptomatic bacteriuria 
related to UPEC) to be consistently important as a fitness factor in comparison with other 
iron acquisition systems under different growth conditions (40). But also other studies 
clearly demonstrated the importance of the iroA system to evade sequestration by host 
protein NGAL due to the altered steric properties of glycosylated ENT (30, 33, 36, 41, 
42). Furthermore, glycosylated ENT features advantageous physical properties such as 
higher solubility and lowered membrane partition coefficients, thus maximising the 
efficiency in membrane-rich environments (37).      
The iroA cluster consists of five genes: iroB, iroC, iroD, iroE, and iroN. Expression of 
these genes, like the ent/fep system, is under the control of the iron-sensing Fur 
transcription regulator, and both the ent and iroA systems are up regulated at the same 
time. The iroA cluster is found in pathogens on chromosomal pathogenicity islands or 
plasmids, suggesting that these genes are mobile and can be transferred by horizontal 
gene transfer. As mentioned previously, the function of the iroA system relies on the 
ent/fep system and involves the synthesis of IroBCDEN proteins to (i) produce 
salmochelin, (i.e., glycosylated ENT), (ii) export and linearize apo-salmochelin, (iii) 
uptake holo-salmochelin, and (iv) degrade of holo-salmochelin in the cytoplasm to 




The first enzyme synthesized from the iroA operon is IroB, a glycosyltransferase that 
catalyses the transfer of glucose moieties onto C5 carbons of ENT catechol groups, thus 
altering the physical and steric properties of the siderophore (43). Since ENT possesses 
three catechol groups, this reaction can occur up to three times under formation of mono-
glycosylated ENT (MGE), di-glycosylated ENT (DGE) and triglycosylated ENT (TGE). 
IroB is the main topic of this work and will be described in Section 1.6 in detail. 
  
IroC, like FepBDGC, is predicted to be an ABC (ATP-binding cassette) transporter 
based on sequence similarities (44). In fact, it was reported that IroC might play similar 
role as FepBDGC, since a FepB-deficient strain was still able to take up linearized 
salmochelins, suggesting that IroC could rescue and import linearized salmochelin (45) 
However, these results were not confirmed in a recent study that identified IroC as being 
able to facilitate excretion of salmochelin arising from IroB activity and ENT (30, 44). 
Furthermore, is was shown that IroC deficient strains gene are no longer able to export 
significant amounts of cyclic DGE (salmochelin S4) or linearized derivates, but only 
monomeric breakdown products such as salmochelin SX (glycosyl-DHB) (46); taken 





Figure 6: Schematic view of the the ent/fep and iroA system working in tandem (30).  
 
IroE is periplasmic esterase associated with the inner membrane (45, 47). Recent 
findings support the hypothesis that IroE plays a significant role for export of apo- 
salmochelin rather than import of holo-salmochelin. Firstly, in vitro studies have shown 
that IroE shows higher affinity for apo-salmochelin and cleaves the trilactone backbone 
of salmochelin only once. This observation goes hand in hand with the relative high 
abundance of linearized derivates of salmochelin in culture medium of iroA harbouring 
strains – IroE-deficient strains, in contrast, secrete only minimal amounts of linearized 
salmochelin (30, 41, 48). The physiological significance of the linearization is possibly 
given by a lowered membrane partitioning coefficient, thus making linearized 
salmochelin more efficient in a membrane-rich environment (37).    
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IroN shows a high sequence similarity to the TonB-dependent ENT receptor FepA and 
has been demonstrated to be necessary for holo-salmochelin import, since salmochelin 
cannot be imported by any other transport system (30). Besides acting as holo-
salmochelin receptor, Feldman et al. even attributed IroN to be an internalization factor 
as demonstrated by an in vitro invasion assay (49). Once holo-salmochelin has been 
imported into the periplasm, it is further processed by the common inner-membrane 
receptor complex FepBCDG and transferred into the cytoplasm.  
 
There, hydrolysis of holo-salmochelin is carried out by IroD. In contrast to IroE, IroD 
cleaves salmochelin multiple times to yield DHB-Ser monomers to facilitate iron release. 
Additionally, IroD shows higher affinity for holo-salmochelin as opposed to IroE  (30).  
 
Now that we have examined the physiological context in which the glycosyltransferase 
IroB is found, a more general introduction to the protein will be provided in the next 
section. The general structural and mechanistic features of glycosyltransferases will be 
examined, followed by a detailed description of the current state of research on IroB. 
 
1.5 Glycosyltransferases 
Glycosyltransferases (EC 2.4.x.y.) are enzymes that catalyse the transfer of a 
carbohydrate moiety from a substituted phosphate leaving group to an acceptor molecule. 
The sugar donor substrate comprises a rather limited range of molecules and is usually a 
nucleoside di-phosphate such as UDP-glucose or GDP-mannose, but also mono-
phosphate and lipid phosphate-activated carbohydrate moieties can be utilized by this 
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class of enzymes (50). As opposed to the narrow range of donor sugar substrate accepted 
by glycosyltransferases, a large variety of acceptor molecules can be glycosylated 
ranging from proteins, lipid, nucleic acids, antibiotics  and oligosaccharides (51, 52).  
Owing to the variety of acceptor molecules, the glycosylation reaction is prevalent in a 
wide range of biological contexts.  Glycosylation plays not only an important role for 
energy storage (Amylum (50)) and the structural integrity of cell walls (cellulose and 
peptidoglycan) in plants and bacteria and proteins (53), but also cell adhesion and 
signalling in immunological contexts (e.g., pathogen recognition by mannose binding 
receptors), glycoprotein trafficking and many more (54). Therefore, it is not surprising 
that glycosyltransferases are encoded in 1-2% of the whole genome sequence; this is true 
for all three domains namely archaea, bacteria and eukarya (50). 
Glycosyltransferases are classified based on sequence and hydrophobic cluster 
similarities by the database CAZy (Carbohydrate-active enzymes) (www.cazy.org). The 
sequence based classification results in useful predictions regarding the stereochemistry 
of the substrate and products in either inverting or retaining glycosyltransferases. In 
addition, information about fold characteristics are provided (55).  
 
1.5.1 Glycosyltransferases: Fold characteristics 
The classification of glycosyltransferases into either a GT-A or GT-B fold was suggested 
in 2001 by Bourne et al. after nine structures of glycosyltransferases had been solved. 
These structures were found to conform to only two distinct folds, named GT-A and GT-
B (56, 57). A representative structure for the GT-A fold is that of SpsA from Bacillus 
subtilis (PDB code: 1QGQ) (58), which is characterized by central, twisted parallel beta 
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sheets that are surrounded by alpha helical structures conforming to a Rossmann fold 
(Figure 7, A). The overall subunit structure is comprised of two distinct N- and C-
terminal domains that are responsible for donor- and acceptor substrate binding (57). 
However, since there is only one central beta strand and the two domains are closely 
associated, this fold is often considered a one-domain fold. Additionally, the GT-A fold 
usually possesses a DXD motif, where the carboxylate groups of aspartic acid are 
involved in divalent metal coordination (50).  
The GT-B fold is represented by the first reported three-dimensional structure for a 
glycosyltransferase, the β-glycosyltransferase of the bacteriophage T4 (PDB code: 1JG7), 
which was solved in 1994 (59). In contrast to the GT-A fold, the GT-B consists of two 
domains of a Rossmann fold-like architecture with central parallel twisted beta sheets and 
helical structures above and below the plane of the central beta strand (Figure 7, B) (50, 
60). The two Rossmann-like domains, namely the N- and C-terminal domains, are 
connected via a flexible linker. Localized between the two domains in a cleft is the active 
site (50). Despite high variability in the primary amino acid sequence, the secondary and 
tertiary structure is highly conserved in the GT-B fold (57, 61, 62). As in the GT-A fold, 
the C-terminal domain is the donor substrate-binding domain and the N-terminal domain 
accommodates the acceptor substrate (50). Not surprisingly, the N-terminal domain 
(acceptor-binding domain) is more variable than the C-terminal domain (donor-binding 
domain), which accounts for the high similarity of the donor substrates and large variety 
of acceptor molecules that can be utilized by glycosyltransferases (63). Notably, the GT-
B fold does usually not exhibit a DXD motif for divalent metal coordination, in contrast 
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to the GT-A fold. Recently, a third fold, GT-C, has been predicted but not yet 
experimentally proven (50). 
 
Figure 7: Cartoon representation of different folds of glycosyltransferases. (A) illustrates the GT-A 
fold of β-glycosyltransferase from bacteriophage T4 (PDB code: 1JG7) and (B) shows the GT-B fold of 
SpsA from Bacillus subtilis (PDB code: 1QGQ). Figures generated using PyMol (Schrödinger, LLC).  
 
1.5.2 Glycosyltransferases: Mechanism 
Glycosyltransferases catalyse the formation of a glycosidic bond between a variety of 
acceptor molecules with nucleophilic groups such as oxygen (O-glycosidic bond), sulfur 
(S-glycosidic bond), nitrogen (N-glycosidic bond), and even carbon (C-glycosidic bond) 
(50). The formation of a C-glycosidic bond is remarkable because of its resilience against 
hydrolysis reactions, enzymatic cleavage, as well as for its rarity among 
glycosyltransferases found in nature (43, 64).  
During formation of the glycosidic bond, the configuration of the anomeric carbon of the 
donor sugar substrate is either inverted or retained in the final glycosylated product. 
Accordingly, glycosyltransferases are classified as retaining or inverting 
glycosyltransferases (50). The mechanism adopted by glycosyltransferases is independent 
of the fold (GT-A or GT-B):  both folds can provide the structural basis for retaining and 
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inverting mechanisms (65). Figure 8 illustrates the differences between the 
stereochemical outcomes of inverting and retaining glycosyltransferases.   
  
 
Figure 8: Illustration of the difference between retaining and inverting glycosyltransferases 
regarding the configuration at the anomeric carbon of the glycosyl donor substrate before and after 
the glycosylation reaction (50). 
 
To date, the mechanism of retaining glycosyltransferases has not been completely 
elucidated (63). Two mechanisms have been suggested: (i) a double displacement 
mechanism (SN2), with a transitional covalently linked glycosyl intermediate in the active 
site (66) and (ii) an SNi-like mechanism, where a oxocarbenium ion intermediate is 
formed and stabilized in the active site. The phosphate leaving group then activates and 
positions the incoming nucleophile for an attack of the anomeric carbon conserving the 
stereochemistry with respect to the anomeric carbon (Figure 9, A) (50, 67). However, 
despite extensive studies performed since the SN2 mechanism was proposed in 1953, an 
intermediate has not been trapped. In contrast, a SNi-like mechanism is now supported by 
quantum mechanical calculations to be energetically favoured (50, 68). This does not 
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exclude the possibility that both mechanisms can be adopted by retaining 
glycosyltransferases (50). 
The mechanism of inverting glycosyltransferases is well established to be a 
straightforward bimolecular nucleophilic substitution (SN2) (Figure 9, B) (69). The 
incoming nucleophile of the acceptor is deprotonated by a base catalyst located in the 
active site of the glycosyltransferase. The nucleophile then attacks the anomeric carbon 
of the carbohydrate moiety of the donor opposite the pyrophosphate group and 
“substitutes” it. This results in the observed inversion of the configuration at the anomeric 
carbon from an α- to a β-configuration, hence glycosylating enzymes employing this 
mechanism are referred to as inverting glycosyltransferases (50).  
Even though inverting glycosyltransferases with either the GT-A fold or the GT-B fold 
use the same SN2 mechanism during catalysis, the method to facilitate the departure of 
the negatively-charged pyrophosphate leaving group is different for these two folds (63). 
As mentioned earlier, the GT-A fold generally features a DXD motif to coordinate 
divalent metal ions. In β-1,4-galactosyltransferase, the metal ion (usually Mn2+) controls 
the sequential order of events, where Mn
2+
  first binds and then facilitates binding of the 
sugar donor. The binding of the sugar donor is followed by loop closure, subsequently 
creating the binding site for the acceptor. Ultimately, during the bimolecular nucleophile 
substitution reaction, the metal ion stabilizes the developing negative charge of the 
phosphate leaving group (70). In contrast, the active site of GT-B glycosyltransferases is 
different. Here the glycosylation reaction is catalysed in a metal-independent manner. 
The departure of the leaving group in these enzymes is stabilized by a helix dipole or a 





Figure 9: (A) Sni like mechanism that is most likely utilized by the majority of the retaining 
glycosyltransferases and (B) illustrates the SN2 mechanism employed by inverting 






Central to the investigation of a SN2 mechanism in glycosyltransferases is (i) the 
elucidation of the identity of the base catalyst that deprotonates the incoming nucleophile 
and, (ii) elucidation of the mechanism involved in stabilization of the pyrophosphate 
leaving group of the donor (50).   
 
1.6 IroB – a pathogen-associated C-glycosyltransferase 
IroB is a C-glycosyltransferase that is a member of the large Family 1 (GT1) along with 
glycosyltransferases from many bacteria, fungi, mammals, plants and viruses. The 
database CAZy (www.cazy.org) identifies IroB (EC 2.4.1.x) as an inverting 
glycosyltransferase that transfers NDP-activated sugars. The fold of IroB has been 
predicted to be that of the GT-B subfamily (55). 
IroB shows significant sequence identity (30%) to the glycosyltransferase CalG3 from 
Micromonospora echinospora (PDB code: 3D0R).  This enzyme is involved in the 
glycosylation of calicheamicin, a prominent antitumor agent (72, 73). IroB also exhibits 
similarity (sequence identity = 23%) to UrdGT2 (PDB code 2P6P), a glycosyltransferase 
involved in biosynthesis of the urdamycin (74). Both of these IroB orthologues have been 
crystallized and have been shown to possess a GT-B fold with characteristics consistent 
with the inverting class of glycosyltransferases.   
It has been clearly demonstrated by in vitro and in vivo studies that IroB alone is 
sufficient and necessary for ENT glycosylation (43, 48). IroB catalyses the sequential 
transfer of glucose moieties from donor UDP-glucose to ENT on a given 2,3-DHB 
(catechol) subunit, resulting in mono-, di- or triglycosylated ENT. During catalysis, a 
25 
 
C-glycosidic bond between the anomeric carbon of the glucose moiety and C5 of an ENT 
catechol is formed. The reaction catalyzed by IroB is shown in Figure 10.   
 
Figure 10: IroB glycosylates ENT in the presence of UDP-glucose by formation of a C-C bond 
between the anomeric carbon of glucose and C5 of catechol group of ENT resulting in mono-, di- or 
triglycosylated ENT (43). 
 
The identity of the C-glycosidic bond as well as the exact position in the DHB subunit 
has been confirmed by extensive NMR studies by two different groups (43, 48). 
Fischbach et al. also found a coupling constant (J = 10 Hz) between C1′ and C2′ protons 
consistent with a β-configuration of the glycoside linkage. This means that the 
configuration of UDP-α-glucose was inverted to a β-configuration during catalysis, 
suggesting that IroB is indeed an inverting glycosyltransferase (43). 
The glycosylation mechanism likely to be adopted by this type of glycosyltransferases is 
that of an SN2 mechanism. The mechanism requires the formation of: (i) a carbon 
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nucleophile that is able to attack the anomeric carbon of the glucose moiety and is 
referred to as direct glycosylation, or (ii) an O-glycosylation at the hydroxyl of the DHB 
subunit followed by a O-C5 rearrangement (43). Both mechanisms for C-glycosylation 
are supported by chemical models, where mechanism (ii) has been proposed mainly for 
ortho-substituted C-glycosylated products. The latter proposal is supported by chemical 
models involving a Lewis acid catalyst that have shown O-C migration to mainly ortho 
and minorly para positions with regard to the hydroxyl group (75-77). The site of 
glycosylation in ENT, however, is para and meta with respect to hydroxyl groups of 2,3-
DHB. Mechanism (ii) would thus require a regiospecific, non-enzymatic step that directs 
the glucose moiety para to 2-hydroxyl of 2,3-DHB. This seems unlikely compared to 
direct C-glycosylation that would occurs in mechanism (i) (43). 
Direct C-glycosylation is similar to a Friedel-Crafts electrophilic, aromatic substitution 
(78) and is enhanced by ortho- and para-directing aromatic substituents such as electron-
rich oxygens of a hydroxyl group that donate electrons to the aromatic system (79-81). 
Fischbach et al. suggested that the ortho/para-directing 2-OH of ENT is deprotonated in 
the IroB active site (Figure 11). Thus the oxygen could donate electrons to the aromatic 
system, resulting in formation of a phenolate anion that is partially delocalized to the 
para C5, rendering this position nucleophilic. In the IroB active site, this C5 position of 
the DHB subunit might be located close to the glucose moiety facilitating attack of the 
anomeric glucose carbon. Such a mechanism would be consistent with the common SN2 
displacement mechanism of inverting glycosyltransferases (43, 50). However, attempts to 
capture the predicted nucleophile in D2O in the absence of the glucose moiety of UDP 
glucose have not been successful (43). A deuterium exchange at C5 would have proven 
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the existence of the C5 carbon anion (43). The lack of exchange does not exclude the 
possibility that the carbon anion is being formed in the presence of the electrophilic 
glucose moiety of UDP-glucose (43, 78).  
In conclusion, the work of Fischbach et al. (43) predicts the presence of a base catalyst 
residue in the active site of IroB that deprotonates 2-OH of DHB subunit of ENT, thus 







































Figure 11: Fischbach et al. suggested that ENT is deprotonated by active site residue in IroB. 







2 Research objective 
The overall major aim of this research project is the identification of possible base 
catalysts in the active site of IroB. In order to achieve this aim, it is essential to predict 
the three dimensional structure of IroB to locate the potential base catalysts in the active 
site. The research described in this thesis can be described by four major goals outlined 
below:  
(1) The first major goal was to predict the three dimensional structure of IroB using 
homology modelling, based on the recently published crystal structure of UrdGT2 (PDB 
code: 2P6P) (74). The primary amino acid sequence of 2P6P shares ~22% sequence 
identity with IroB, and is thus a promising template to predict the three dimensional 
structure of IroB. The predicted structure will then be used as a guide and possible base 
catalysts will be identified.  
(2) The second major goal was the expression and purification of IroB, as well as the 
establishment of an in vitro activity assay for IroB using the published methods of 
Fischbach et al. as a guide (43). Mutagenesis of predicted base catalysts, identified in the 
homology model of IroB, could then be performed to assess the influence of the 
identified residues on catalysis in comparison with wild-type IroB. These experiments 
provided valuable information about the role of various residues during IroB catalysis. 
(3) The third major goal involved the biophysical characterization of wild-type IroB and 
mutants, and is thus highly complementary to first and second goals outlined above.  
Experimental verification for the homology model was attained via complementary 
biophysical methods such as circular dichroism and fluorescence spectroscopy. 
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Additionally, the overall structural integrity of mutagenized IroB variants was confirmed 
by these methods.  
(4) The fourth and final major goal involved the development of an acceptor (ENT) 
binding assay to assess the effects of mutations performed on IroB. The apparent 
equilibrium binding affinity constant (KD’) for ENT binding to IroB (wild-type and 
variant proteins) was determined using a published method for this purpose (82). These 
data provided further information about the structural integrity of the variants and their 
ability to bind ENT, as well as further information about the role of mutagenized residues 
for binding and catalysis. 
 
The biochemical and biophysical characterizations of IroB described in this thesis 
advances our understanding of the mechanism of an uncommon yet important class of 
glycosyltransferases that transfers sugar moieties via formation of a C-glycosidic bond.  
As mentioned elsewhere, this type of bond is not susceptible to chemical and enzymatic 
hydrolysis and thus considered stable. These studies comprise an unprecedented 
investigation into structure and mechanism of a C-glycosyltransferase from a clinically 
relevant extraintestinal pathogen.   
 
    
 




In this chapter all reagents used in the course of this work are listed. Additionally, 
composition of all buffers and solutions is described. 
 
3.1 Reagents, kits and enzymes 
In the following table (Table 2) all chemicals, reagents and kits are listed under 
specification of the manufacturer and catalog number and thus defining their purity. 
 
Table 2: important reagents, kits and enzymes are listed with manufacturer and catalog number. If 
the country is not mentioned the company is located in Canada. 
Product Manufacturer CAT# 
2-Propanol Thermo Fisher, Waltham, MA, USA A416-4 
a, a, Dipyrdiyl Thermo Fisher, Waltham, MA, USA D-95 
Acetic acid Thermo Fisher, Waltham, MA, USA 351271-212 
Acetonitrile Thermo Fisher, Waltham, MA, USA A998-4 
Acrylamide-Bis-Acrylamide 
19-1 Mixture 
Quantum Biotechnologies, Montreal, PQ BIAC11 
Agarose BioShop Canada Inc., Burlington, ON AGA001.500 
Ammonium Persulfate BioShop Canada Inc., Burlington, ON AMP001.25 
Ammonium Sulfate Thermo Fisher, Waltham, MA, USA BP212-212 
Bio-Tryptone BioShop Canada Inc., Burlington, ON TRP402.1 
Blotting Grade Blocker, Non-
Fat Dry Milk 
Biorad, Hercules, CA, USA 170-6404 
BME BioShop Canada Inc., Burlington, ON MER002.100 
Bromophenol Blue Biorad, Hercules, CA, USA 161-0404 
CaCl2×2H2O BioShop Canada Inc., Burlington, ON CCL444 
Centrifugal Devive Nanosep 
10K Omega 
PALL Life Science, Ann Arbor, MI, USA OD010C34 
Coomassie Brilliant Blue 
G-250 
Biorad, Hercules, CA, USA 161-0406 
Desalting Columns  
Pac 10 DG 
Biorad, Hercules, CA, USA 732-2010 
D-Glucose BioShop Canada Inc., Burlington, ON GLU501.1 
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Product Manufacturer CAT# 
DMSO Caledon Laboratories, Georgetown, ON 4100-1 
DTT BioShop Canada Inc., Burlington, ON DTT001.1 
EDTA BioShop Canada Inc., Burlington, ON EDT001.500 
ENT Sigma Aldrich, St. Louis, MO, USA M3910-1MG 
Ethanol n/a n/a 
Ferric Chloride BioShop Canada Inc., Burlington, ON FER002.250 
Formic acid Sigma Aldrich, St. Louis, MO, USA 94318 
Glycerol Thermo Fisher, Waltham, MA, USA BP229-4 
Glycine BioShop Canada Inc., Burlington, ON GLN001.5 
Goat Anti-Rabbit IgG (H+L)-
HRP Conjugate 
Biorad, Hercules, CA, USA 170-6515 
HEPES BioShop Canada Inc., Burlington, ON HEP001.1 
iBlot Gel Transfer stacks Invitrogen, Carlsbad, CA, USA IB3010-02 
Imidazole BioShop Canada Inc., Burlington, ON IMD508.500 
iProof HighFidelity Biorad, Hercules, CA, USA 172-5301 
IPTG BioShop Canada Inc., Burlington, ON IPT001.10 
Kaleidoscope, prestained 
standards 
Biorad, Hercules, CA, USA 161-0324 
Kanamycin BioShop Canada Inc., Burlington, ON KAN201.10 
KCl n/a n/a 
KH2PO4 BioShop Canada Inc., Burlington, ON PPM666.1 
Magensium Cloride BioShop Canada Inc., Burlington, ON MAG520.500 
Magnesium Sulfate BioShop Canada Inc., Burlington, ON MAG522 
Methanol Caledon Laboratories, Georgetown, ON 6700-3 
Na2HPO4 BioShop Canada Inc., Burlington, ON SPD579.1 
NaCl n/a n/a 
NAP5 GE Healthcare, Little Chalfont, 
Buckinghamshire, UK 
17-0853-02 
NH4Cl BioShop Canada Inc., Burlington, ON AMC303 
Ni-NTA Superflow Quiagen, Hilden, NRW, Germany  30430 
OTG BioShop Canada Inc., Burlington, ON OGP202.5 
PfuTurbo Agilent, Santa Clara, CA, USA 600250-52 
Plasmid DNA Kit Bio Basic Inc., Markham, ON BS414/100Preps 
Protease Inhibitor Cocktail BioShop Canada Inc., Burlington, ON PIC002 
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Product Manufacturer CAT# 
Restriction Enzymes NEB, Ipswich, MA, USA n/a 
Reverse Transcriptase NEB, Ipswich, MA, USA M0253L 
RP column   
SDS, 20% solution BioShop Canada Inc., Burlington, ON SDS002.500 
Sodium Bicarbonate BioShop Canada Inc., Burlington, ON SOB999.500 
Sodium Hydroxide n/a n/a 
Spectra/Por Dialysis 
Membrane MWCO 25 kDa 
Spectrum Laboratories Inc., Rancho 
Dominguez, CA, USA 
132554 
Sucrose BioShop Canada Inc., Burlington, ON SUC507.5 
SV Total RNA Isolation Kit Promega, Madison, WI, USA Z3100 
SYBR Safe DNA gel stain Invitrogen, Carlsbad, CA, USA S33102 
TCEP BioShop Canada Inc., Burlington, ON TCE101.10 
TEMED BioShop Canada Inc., Burlington, ON TEM001.25 
TEV protease Promega, Madison, WI, USA V6051 
TFA Acros Organics, Geel, Antwerp, Belgium 13972-1000 
Tris Bio Basic Inc., Markham, ON TB0196 
Tween 20 BioShop Canada Inc., Burlington, ON TWN510.250 
Uridine5’-diphosphoglucose 
disodium salt (UDP) 
Sigma Aldrich, St. Louis, MO, USA U4625-25MG 
Yeast Extract BioShop Canada Inc., Burlington, ON YEX401.1 
ECL Thermo Fisher, Waltham, MA, USA 32109 
 
3.2 E. coli strains 
The strain DH5α (Invitrogen) bears following genotype and was used for cloning: 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-
1 hsdR17 
Because of recA1 and endA1 mutations internal recombination events and endonuclease 
activity are reduced resulting in high plasmid yield.  
For the expression of IroB the E. coli strain BL21 (DE3) was used. BL21 (DE3) 
possesses following genotype: 
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F- ompT hsdSB (rB-mB-) gal dcm (DE3) 
This strain codes for the T7-polymerase under control of a lacUV5 promoter. It is 
localized on a Lambda prophage in the attλ. Furthermore, BL21 (DE3) is well suited for 
protein expression because of its minimized protease activity. 
The strain Nissle 1917 (Mutaflor) is listed under DSM No. 6601 in the ”German 
Collection for Microorganisms and Cell Cultures” (http://www.dmsz.de) and was kindly 
provided by Klaus Hantke (University of Tübingen, Germany). Nissle 1917 is non-
pathogenic due to lack of virulence factors such as alpha-hemolysin, P-fimbrial adhesins, 
and the semirough lipopolysaccharide phenotype, but harbours the iron acquisition 
system iroA (83). 
The E. coli strain AG1, a common cloning strain distributed by Stratagene,  was used as 
negative control (iroA
-
) and harbours the following genotype: 
recA1 endA1 gyrA96 thi-1 hsdR17 (rK– mK+) supE44 relA1 
 
3.3 Plasmid 
The expression vector pET24b (Novagen) was used throughout these studies and was 
adapted accordingly. This vector possesses a f1 origin of replication and kan
R
 selection 
marker. Genes encoding recombinant proteins were cloned under control of a T7 
promoter in-frame with C-terminal  His6 tag. 
  
3.4 Genomic DNA CFT073 
Genomic DNA from uropathogenic E.coli CFT073 (ATCC700928D-5) was obtained 
from the ATCC (ATCC, Manassas, VA) and stored at -20 °C.  
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3.5 Polyclonal anti-IroB antibody (rabbit) 
The polyclonal antibody anti-IroB was raised using the services of Open Biosystems 
(Open Biosystems Inc., Huntsville, AL). The antibody was first raised in a 90-day 
protocol in rabbit PA4061 (Project number: PFS221108) and then further affinity-
purified against purified, recombinant IroB. The purification resulted in ~ 5 mL purified 
antibody solution (concentration 0.464 mg×mL
-1
, Titer 5 ng), which was then stored in 
50% (v/v) glycerol with a final concentration of 0.232 mg×mL
-1
 at -80 °C.    
 
3.6 Primer 
Primers were obtained from BioCorp DNA Inc, Canada. Lyophilized primers were 
resuspended in dH20 to a final concentration of 100 µM and stored at -20 °C. Primer 
sequences and modifications are listed in Table 3. 
  
Table 3: List of primers used for plasmid construction including sequence and modifications. 
Restriction recognition sites are underlined. 









IroB (NH6/TEV-387) FW GGATCCATGCGTCGACTGCCTGATTTAGATCGTC 
IroB (NH6/TEV) RV CTCGAGTTACCCTTTCTGTACCATTGTGATCAGGC 
IroB (NH6/TEV-371) FW GGATCCATGCGTATTTTGTTTGTAGGCCCGC 
IroB (CH6) FW GGAATTCCATATGCGTATTTTGTTTGTAGGCCCGC 
IroB (CH6) RV GATCGAATTCGGCCCTTTCTGTACCATTGTGATCAGG 
W264L FW GTTCGCCTGGTTGACTTGATACCCATGGGTGTC 
W264L RV GACACCCATGGGTATCAAGTCAACCAGGCGAAC 
H138L FW GCCATACCCCCTGGCTTATCAGGGGTGTAAC 
H138L RV GTTACACCCCTGATAAGCCAGGGGGTATGGC 
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Primer Sequence (5’-3’) 
E60L FW CCCGGTCTGGATTCCTTAGCTGGTTACCGCCA 
E60L RV TGGCGGTAACCAGCTAAGGAATCCAGACCGGG 
D304N FW GGCCAGGGAGCCAATCGCCCGGTAA 
D304N RV TTACCGGGCGATTGGCTCCCTGGCC 
H6566A FW CCGAAGCTGGTTACCGCGCCGCTGAGGCACAGCGGAAAA 
H6566A RV TTTTCCGCTGTGCCTCAGCGGCGCGGTAACCAGCTTCGG 
E67A FW GTTACCGCCACCATGCGGCACAGCGGAAAAA 
E67A RV TTTTTCCGCTGTGCCGCATGGTGGCGGTAAC 
 
3.7 Culture Media 
As necessary, kanamycin (concentration 30-50 µg/ml) was added after liquid media was 
cooled down to ~50 °C after autoclaving.  The pH of culture media was adjusted by the 
addition of 1 M NaOH. The Inductor solution was sterilized using a 0.2 µm syringe filter. 
 
Inductor solution 
 IPTG 1 M in dH2O 
 
LB-Medium (pH 7.0) 
 Peptone 10 g×L
-1
 
 Yeast extract 5 g×L
-1
 
 NaCl 5 g×L
-1





 Agar 1.5 % (w/v) in LB-Media 
 
2x YT-Medium (pH 7.0) 
 Peptone 16 g×L
-1
 
 Yeast extract 10 g×L
-1
 
 NaCl 5 g×L
-1













NH4Cl  18.7 mM 
 MgSO4 2 mM 
 C6H12O6 22 mM 
 CaCl2 0.1 mM 
 
3.8 Buffers and solutions 
In this chapter all buffers and solutions are defined under specification of component, 
their final concentration and solvent. Their use is described in Chapter 4.  
 
3.8.1 Purification buffer 
Preparation and adjustment of pH was carried out at RT. Buffer were then sterile filtered, 
degassed and stored at 4 °C, not longer than 3 days.   
 
Cell Disruption/Binding Buffer  
 Tris-Cl (pH 8.5) 20 mM 
 PIC (100x) 1x  
 NaCl 500 mM 
 Imidazole 20 mM 
 TCEP 2 mM 
 Sucrose 500 mM in dH2O 
 
Wash Buffer  
 Tris-Cl (pH 8.5) 20 mM 
 KCl 25 mM 
 Imidazole 40 mM 
 TCEP 1 mM 




Elution Buffer  
 Tris-Cl (pH 8.5) 20 mM 
 KCl 25 mM 
 Imidazole 250 mM 
 TCEP 1 mM 
 Sucrose  1 M in dH2O 
 
EDTA  
 EDTA (pH 8.0) 100 mM in dH2O 
 
Dialysis Buffer  
 Tris-Cl (pH 8.5) 20 mM 
 KCl 25 mM 
 TCEP 1 mM 
 Sucrose 1 M in dH2O 
 
Dialysis Membrane Washing Solution 
 CHNaO3 25 mM 
 EDTA 25 mM in dH2O 
 
3.8.2 Buffers for Activity Assay 
The pH of buffers was adjusted at RT. Buffer were degassed, sterile filtered using a filter 
with 0.2 µm pore size and stored at 4 °C. 
 
Activity Assay Buffer (AAB1) (used in LC-MS)  
 Tris-Cl (pH 7.5) 75 mM 
 TCEP 2.5 mM 






Activity Assay Buffer (AAB2) (used for comparison of variants)  
 HEPES-NaOH (pH 7.5) 75 mM 
 TCEP 2.5 mM 
 Glycerol  50% (v/v) in dH2O 
 
UDP-Glucose Stock 
 Tris-Cl (pH 7.5) 75 mM  
 UDP-Glucose 100 mM in dH2O 
 
Enterobactin Stock 
 Enterobactin 14.9 mM in DMSO 
 
3.8.3 Buffers for Fluorescence-Based Quenching Assay 
FBQA-Buffer  
 
 HEPES-NaOH (pH 7.5) 75 mM 
 TCEP 2.5 mM 
 MgCl2 5 mM in dH2O 
 
Enterobactin  
 Enterobactin (Sigma) 2.98 mM in DMSO 
 
3.8.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
In this chapter buffers are listed that were used in the course of electrophoretic separation 
of proteins using SDS-PAGE. Colloidal Coomassie Blue (Blue Silver (84)) stain was 
used for detection of proteins in a polyacrylamide gel.  
 
Running Buffer (10x) 
 Tris 30.3 g×L
-1
 
 Glycine 144 g×L
-1
 
 SDS 1% (w/v) in dH2O 
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Sample Buffer (5x)  
 Tris (pH 6.8) 250 mM 
 BME 250 mM 
 BPB 0.25% (w/v) 
 SDS 5% (w/v) 
 Glycerol 25% (v/v) in dH2O 
 
Blue Silver Stain 
 (NH4)2SO4 100 g×L
-1 
 
Coomassie G-250 1.2 g×L
-1 
 H3PO4 10% (v/v) 
 
MeOH 20% (v/v) in dH2O 
 
3.8.5 Immunodetection 




 Tris-Cl (pH 8.0) 75 mM 
 DTT 5 mM 
 OTG 1% (w/v)  
 PIC (10x) 1x 






PBS (10x) (pH 7.4) 
 NaCl 80 g×L
-1
 
 KCl 2 g×L
-1
 
 Na2HPO4 14.4 g×L
-1
  




PBST (pH 7.4) 





 Skim milk powder 5% (w/v) in PBST 
 
3.9 Software 
For the purpose of modelling of protein structures the software Modeller v9.9 (San 
Francisco, CA) was used (85-88).  Protein structures were visualized using PyMol (The 
PyMOL Molecular Graphics System, Schrödinger, LLC) and superposition of protein 
structures was performed using the software LSQMAN (LSQMAN, Uppsala, Sweden) 
(89, 90). Model structures were validated using the VADAR software suite (91) and 
ProSA-web (92, 93). Data plotting and fitting was carried out using the software 
OriginLab v8.6 (OriginLab, Northampton, MA). Topology maps were produced by 
TopDraw (94). The molar extinction coefficient of protein from the primary amino acid 
sequence was determined using the ProtParam tool from the ExPASy Server (95). 
Sequence alignments carried out using T-Coffee (96) or PSI-Coffee (97) and alignments 





In this chapter all the methods are described in detail, underlying functional principles are 
described as necessary. 
 
4.1 Plasmid construction 
The parental vector for all constructs was pET24b. All cloning steps were carried out 
according to standard cloning methods described in Sambrook et al. (99). For all cloning 
steps the E. coli strain DH5α was used and final expression construct was transformed 
into BL21 (DE3). 
 
4.1.1 pET24b-IroB-CH6 
The expression construct pET24b-IroB-CH6 was constructed as described by Fischbach 
et al. (43). Briefly, the iroB gene was amplified from genomic DNA (CFT073) using 
primer IroB (CH6) FW and IroB (CH6) RV, where the forward primer introduced an 
NdeI site and the reverse primer a EcoRI site, respectively. The amplification was 
performed using iProof DNA polymerase (Biorad) according to standard protocols. After 
digestion of the PCR product (insert) and the parental vector pET24b (vector) with NdeI 
and EcoRI, the insert was ligated into the vector under control of a T7 promoter in-frame 
with a C-terminal His6 affinity tag. The resulting vector, namely pET24b-IroB-CH6, was 
transformed into DH5α and sequence identity was verified by sequencing. The protein 





For the constructs pET24b-IroB-NH6/TEV-373 and -389, respectively, the parental 
vector pET24b had to be modified first to introduce an N-terminal His6 affinity tag, as 
well as a TEV protease recognition site to allow cleavage of the tag in the final, 
recombinant protein. For this purpose we designed two complementary primers, namely 
nMCS(p1) and nMCS(p2), with 5’ phosphorylation resembling a NdeI and BamHI 
digested cutting site with corresponding 5’ overhang (sticky ends). After annealing of 
these primers by mixing equimolar amounts, heating to 95 °C followed cooling to RT, 
the resulting double stranded insert was directly ligated into NdeI and BamHI digested 
pET24b and transformed into DH5α. The intermediate pET24b-nMCS was isolated and 
served as the parental vector for the constructs described in Section 4.1.3 and 4.1.4. 
 
4.1.3 pET24b-IroB-NH6/TEV-373 
The iroB gene was amplified from genomic DNA (CFT073) using primer IroB 
(NH6/TEV-371) FW and IroB (NH6/TEV) RV, which introduced BamHI and XhoI 
restriction sites. For the amplification iProof DNA Polymerase was used.  The PCR 
product (insert) was digested with BamHI and XhoI, as well as the parental vector 
pET24b-nMCS (construction described in 4.1.2). The digested insert and vector were 
ligated, resulting in the expression construct pET24b-IroB-NH6/TEV-373 with the iroB 
gene in frame with a N-terminal His6 and a TEV protease recognition site. The protein 
product has a length of 373 aa after removal of the N-terminal hexahistidine and linker 
region, and is henceforth referred as IroB-NH6/TEV-373.  The construct was transformed 




For the construct pET24b-IroB-NH6/TEV-389 the iroB gene was amplified with iProof 
DNA polymerase using the forward primer IroB (NH6/TEV-387) FW and IroB 
(NH6/TEV) RV. The primer FW introduced a BamHI site and the primer RV introduced 
an XhoI site, respectively. After digestion of the PCR amplified iroB gene (insert) with 
BamHI and XhoI, it was ligated into pET24b-nMCS (construction described in 4.1.2) that 
was digested correspondingly. The resulting expression vector pET24b-IroB-NH6/TEV-
389 contained the iroB gene with an N-terminal extension in frame with the N-terminal 
His6 tag cleavable by TEV resulting in a protein length after cleavage with TEV protease 
of 389 aa, and is thus henceforth referred as IroB-NH6/TEV-389. The vector was 
transformed into E. coli DH5α and verified by sequencing. 
 
4.1.5 Site-directed mutagenesis 
To introduce mutations into the iroB gene, mismatch PCR was used. To achieve the 
desired mutations, 1-3 nucleotides in the middle of the primer were changed to alter the 
corresponding codon encoded in the PCR-template. Site-directed mutagenesis was 
carried out according to the QuikChange system (Stratagene) using the following primer 
pairs W264L FW and RV (Tryptophan 264 to Leucine, H138L FW and RV (Histidine 
138 to Leucine), E60L FW and RV (Glutamic acid 60 to Leucine), D304N FW and RV 
(Aspartic acid 304 to asparagine), H6566A FW and RV (Histidine 65 and 66 to alanine), 
E67A FW and RV (Glutamic acid 67 to alanine). PCR reactions were conducted using 
PfuTurbo DNA polymerase according to the standard protocol for this polymerase in a 2 
step PCR (18 cycles) with primer annealing and extension at 72 °C for 10 min and using 
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pET24b-IroB-CH6 as a template. Prior to transformation into DH5α the parental vector 
was digested with DpnI. All mutagenized expression constructs were verified by 
sequencing.         
 
4.2 Protein expression 
For expression of IroB, the expression vectors pET24b-IroB-NH6/TEV-373, pET24b-
NH6/TEV-389, pET24b-IroB-CH6 or mutagenized derivatives were used. These 
expression constructs contain the gene encoding E. coli IroB under control of a T7-phage 
promoter and were transformed into the expression strain E. coli BL21 (DE3). This strain 
carries the gene encoding T7-polymerase on a λ-prophage under control of a lacUV5 
promoter; therefore, expression of the transgene can be induced by addition of the 
synthetic inducer IPTG. BL21 (DE3) cells harbouring pET24b-IroB-CH6 or mutagenized 
derivatives were streaked on LB-agar plates containing 50 µg×mL
-1
 kanamycin.  
An overnight culture grown in LB medium (supplemented with 50 µg×mL
-1
 kanamycin) 
was inoculated from a single colony from a LB-agar plate and grown to stationary phase 
at 37 °C and 220 rpm. The expression was then conducted in 3 L Fernbach flasks filled 
with 1 L 2x YT media (supplemented with 30 µg×mL
-1
 kanamycin), where the initial 
culture was diluted 1:100 in 2x YT medium. The expression culture was grown at 37 °C 
and 220 rpm until it reached an OD600 nm = 0.4-0.6. The expression of the transgene was 
then induced with 400 µM IPTG and was allowed to proceed for 20 h at 20 °C and 
220 rpm. The cells from 1 L culture were then pelleted by centrifugation 6000×g for 20 
min at 4 °C and stored at -20 °C until use.  
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4.3 Protein purification/storage 
Cells from 1 L culture were resuspended in 30 mL cold Disruption/Binding Buffer 
(supplemented with PIC prior to use) using a tissue homogenizer and lysed through 
three passes French Press operated at 16000 to 18000 lb×in
-2
. During the whole 
procedure the cell lysate was kept cold. Insoluble matter and cell debris were removed by 
ultracentrifugation operated at 130000×g, 4 °C for 1 h. Using a BioRad Biologic 
DuoFlow FPLC, the clarified supernatant was immediately applied to a 10 mL Ni
2+
-NTA 
Superflow (Qiagen) column, pre-equilibrated with Disruption/Binding Buffer, at a flow 
rate of 1 mL×min
-1
 and washed at a flow rate of 3 mL×min
-1
 with 100 mL 
Disruption/binding Buffer. In the next step the buffer was switched to Washing Buffer 
(40 mM Imidazole) using a gradient at a flow rate of 3 mL×min
-1
 in a volume of 20 mL 
and then washed at the same flow rate with 20 mL. The elution was conducted in one step 
in Elution buffer (250 mM Imidazole) at a flow rate of 3 mL×min
-1
. Fractions were 
pooled, immediately placed on ice and EDTA pH 8 to a final concentration of 1 mM was 
added to chelate any Ni
2+
 leached from the column.  
The dialysis membrane (Spectra/POR 6; MWCO: 25 kDa) was in the first instance 
washed in dH2O and subsequently in 50% (v/v) EtOH. Afterwards the membrane was 
incubated under slow stirring in Dialysis Membrane Washing Solution for 30 min at RT 
and finally the membrane was washed in dH2O under slow stirring for 10 min. 
The pooled fractions from protein purification were dialysed using the primed dialysis 
membrane against 4 x 1 L Dialysis Buffer for at least 4 h each under constant stirring at 
4 °C. After finishing the dialysis procedure the protein solution was sterile filtered 
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(0.2 µm pore size) and directly dripped into liquid N2. The beads followed from this 
procedure were collected and stored at -80 °C.  
      
4.4 Determination of protein concentration 
The protein concentration was determined spectroscopically at 280 nm using molar 









, respectively. Extinction coefficients were predicted from primary 
amino acid sequences using the ProtParam tool (http://web.expasy.org/protparam/). 
These predicted extinction coefficients were also used for IroB-CH6-E60L, IroB-CH6-
E67A, IroB-CH6-D304N, IroB-CH6-H6566A, IroB-CH6-D304N, IroB-NH6/TEV-373 









 was used for IroB-CH6-W264L, reflecting 
the change in primary sequence. All extinction coefficients were calculated using 
ProtParam tool from the ExPASy server (95). 
  
4.5 Identification of iroB gene product 
To identify the iroB gene product in E. coli Nissle 1917 we designed experiments to 
measure iroB expression at the mRNA and protein levels.  
 
4.5.1 RNA-isolation and transcription to cDNA 
E. coli Nissle 1917 and AG1 were first grown to saturation in 2x YT medium at 37 °C 
and 220 rpm overnight. The cells were then pelleted at 2000×g at 4 °C and 10 min and 
washed twice with M9 minimal media to remove excess nutrients from rich medium 
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before. Finally, Nissle 1917 and AG1 were cultivated at 37 °C and 220 rpm. The OD600 at 
the beginning of the cultivation was 0.83 and was aborted after 5 h when an OD600 of 2.41 






 cells (~ 0.5 
mL) were pelleted and used in RNA-isolation procedure (100).  
The total RNA was isolated from the Nissle 1917 pellet obtained using the SV Total 
RNA Isolation System (Promega). The standard procedure described in the Quick 
protocol of the manufacturer was applied and the RNA was finally eluted in 100 µL 
RNase-free H2O. The isolated mRNA was stored at -80 °C, whereas 10 µL were directly 
used in the reversed transcription reaction to obtain cDNA from mRNA. The reaction 
was set up according to the standard protocol M-MuLV Reverse Transcriptase (NEB), 
where 10 µL of eluent were mixed with primer IroB (CH6) RV and dNTP mix and 
heated to 65 °C for 5 min. After this incubation period 400 U of Reverse Transcriptase 
and the corresponding buffer supplied by the manufacturer were added to a final volume 
of 20 µL and the reaction allowed to proceed for 1 h at 42 °C in the absence of RNase 
inhibitor. Subsequently the enzyme was inactivated at 90 °C for 10 min and the cDNA 
stored at -20 °C until further use. 
 
4.5.1.1 PCR reaction to amplify cDNA 
In order to identify the iroB gene product, the cDNA resulting from the isolation 
procedure described in 4.5.1 was amplified with primer pair that was specific for either 
the iroB gene product with a length of 1113 bp or 1161 bp. For this purpose the reactions 
described in Table 4 were set up. The PCR reaction was conducted according to the 
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standard protocol for iProof DNA polymerase (Biorad) with a primer annealing 
temperature of 72 °C, 45 s extension time and 25 cycles. 
     
Table 4: composition of PCR-reactions to identify iroB gene product from cDNA and corresponding 
control reactions to demonstrate primer specificity.  















IroB (NH6/TEV-387) FW - 0.3 µM - 0.3 µM 
IroB (NH6/TEV) RV 0.3 µM 0.3 µM 0.3 µM 0.3 µM 
IroB (NH6/TEV-371) FW 0.3 µM - 0.3 µM - 
DMSO (100%) 3% (v/v) 3% (v/v) 3% (v/v) 3% (v/v) 












iProof Buffer (5x) 1x 1x 1x 1x 
ddH2O ad 50 µL ad 50 µL ad 50 µL ad 50 µL 
 
The amplified product after exposing the reaction mix to typical PCR temperature cycles 
was analyzed on a 1% (w/v) agarose gel in TAE buffer according to standard procedure 
from Sambrook et al. (99) and DNA was detected with SYBR Safe DNA stain.  
 
4.5.1.2 Detection of IroB using Western Blot 
E. coli Nissle 1917 harbouring the iroA cluster and E.coli AG1 as the negative control 
(iroA
-
) were grown first grown to saturation in LB media (no antibiotics) at 37 °C and 
220 rpm. The cells were then pelleted at 2000×g at 4 °C for 10 min and washed once with 
M9 minimal medium (supplemented with 100 µM 2,2-dipyridyl). The cells were then 
resuspended in M9 minimal media supplemented with 100 µM 2,2’-dipyridyl, and 
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cultivated under constant shaking at 220 rpm at 37 °C for 20 h. The OD600 at beginning of 
the cultivation was 0.18 for Nissle 1917 and 0.29 for AG1. After 20 h cultivation Nissle 
1917 reached an OD600=1.43 under the cultivation conditions, whereas the AG1 cells 
reached an OD600=0.75. The cells were harvested by centrifugation and stored at -20 °C.  
For SDS-PAGE and the following immunodetection 100 mg (wet weight) AG1 and 
Nissle 1917 cells were lysed in BugBuster for 1 h at RT and samples were prepared and 
separated using 8% polyacrylamide gel according to Laemmli et al. (101). For 
comparison IroB NH6/TEV-373 and IroB NH6/TEV-389 were digested with TEV 
protease according to the manual supplied by the manufacturer and also prepared and 
separated on the same gel. Subsequently to separation proteins were transferred onto 
nitrocellulose membrane using iBlot Transfer system (Invitrogen). For immunodetection, 
the membrane was initially blocked in Blocking solution for 30 min at constant shaking 
and then incubated with the polyclonal anti-IroB (rabbit) antibody (final antibody 
concentration 4.64 ng×µL
-1
) in Blocking solution for 45 min. After the incubation in the 
primary antibody the membrane was washed 3 times for 10 min with PBST under 
constant shaking. Then the secondary antibody Anti-Rabbit IgG (goat) conjugated with 
HRP was applied in a dilution of 1:3000 in Blocking Solution for 1 h under constant 
shaking. The membrane was finally washed 3 times for 10 min in PBST and 
subsequently incubated for 2 min in entry-level peroxidase substrate for enhanced 
chemiluminescence (ECL). Protein bands were visualized on autoradiography film using 
a short exposure of 1-2 s.     
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4.6 Homology modeling using Modeller v9.9 
Due to the absence of any experimental structural data for IroB, we decided to predict the 
three-dimensional structure of IroB by homology modeling. The procedure consists 
basically of fold assignment, target-template alignment, model building, and model 
evaluation (85). A suitable template, the C-glycosyltransferase UrdGT2 from 
Streptomyces fradiae (PDB code: 2P6P), was identified using the FFAS03 server 
(http://ffas.ljcrf.edu/ffas-cgi/cgi/ffas.pl) (42-44) by comparison with the IroB primary 
amino acid sequence (NCBI reference: ACA34771.1) as published in Tivendale et al. 
(102). Target- and template alignment and model building was carried out using Modeller 
v9.9  according to a protocol published in Current Protocols in Protein Science (85). 
Structural superposition of IroB-model with UrdGT2, as well as the superposition with 
CalG1 (PDB code: 3OTH) to identify the donor- and acceptor binding site, was 
performed using LSQMAN; this software was also used to determine RMSD values of 
superposition (89, 90).   The integrity of the IroB model structure was evaluated using the 
implemented tools of Modeller v9.9 (29-31), VADAR (91) and ProSA-web (92, 93) 
tools. 
 
4.7 Activity assay 
The activity assay described in the next two sections (4.7.1 and 4.7.2) differs only 
minimally in terms of the buffer that was used. During establishment of this activity 
assay in our lab, based on the method described in Fischbach et al. (43), we realized that 
IroB heavily precipitates in the absence of glycerol (Section 4.7.1). Therefore we 
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stabilized IroB in the course of this project and used a different buffer for the comparison 
of IroB WT and mutants (Section 4.7.2).  
 
4.7.1 LC-MS to detect MGE/DGE/TGE 
IroB-CH6 prepared and stored according to method described in 4.3 was thawed and 
exchanged AAB1 using an equilibrated NAP5 DNA desalting column according to the 
manual supplied by the manufacturer. Briefly, 0.5 mL of IroB containing protein solution 
was applied to the column and allowed to enter the resin. The protein was then eluted in 
1 mL of AAB1 buffer. Approximately, 5 µM IroB were mixed with 100 µM ENT and 
600 µM UDP-glucose and the conversion to MGE/DGE and TGE was allowed to 
proceed at RT. After 5 min, 40 min and 80 min time points, aliquots were taken, 
quenched with 10% (v/v) ACN and supernatant subjected to LC-MS analysis after 
centrifugation (1 min at 21100×g at RT). Unbound sample was removed by washing for 
10 min at 0% ACN in 0.05% (v/v) FA in ddH20 at a flow rate of 300 µL×min
-1
. ENT and 
the conversion products MGE/DGE/TGE were then separated in a gradient from 0-80% 
ACN in 0.05% FA in ddH2O over 30 min at a flow rate of 300 µL×min
-1
 and directly 
injected in ESI-MS Qtof2 (CBAMS) and mass spectrometric analysis of ENT and IroB 
products (MGE, DGE, TGE) was performed in positive mode. 
 
4.7.2 Comparison of IroB mutants 
IroB-CH6 and corresponding mutants were exchanged in buffer AAB2 using a 
equilibrated DG10 desalting column according to the minimal dilution protocol supplied 
by the manufacturer. Specifically, 0.1 to 1.0 mL of protein solution, purified and stored 
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as described in Section 4.3, was loaded on the column and the liquid was allowed to enter 
the resin. Dependent on the volume loaded buffer AAB2 was then added to 3 mL and 
also allowed to reach the surface of the resin. The sample was then eluted with 1.5x 
volume of the sample volume in AAB2 buffer, and the protein concentration was 
determined spectroscopically as described in Section 4.4. The enzymatic reaction, in 
which ENT is eventually converted to MGE/DGE/TGE by IroB, was prepared in PCR 
tubes in a volume of 100 µL in containing 2 µM IroB, 100 µM ENT, 600 µM UDP-
glucose and 1 mM MgSO4 in AAB1 buffer and was allowed to proceed for 1 h at 25 °C. 
After this time, 80 µL was directly separated by HPLC (Agilent) using a reversed-phase 
C18 column at a flow rate of 1 mL×min
-1
. The sample was loaded and unbound material 
was washed for 10 min in 5% (v/v) ACN in ddH2O and then separated in a gradient from 
5-80% (v/v) ACN in 0.05% (v/v) TFA in ddH2O over 20 min and was monitored at 
254 nm. The chromatogram was exported and reconstructed using the software 
OriginLab v8.6. 
 
4.7.3 Activity assay in the absence of Mg2+ and presence of Fe3+ 
Divalent metal ions such as Mg
2+
 ions are often needed by glycosyltransferases due to 
mechanistic requirements to stabilize positively charged leaving groups during catalysis. 
We also tested the activity in the presence of Fe
3+
 to occupy the hydroxyl groups of the 
catechol groups of ENT. The ENT molecule binds ferric ions with high affinity and the 
coordination of iron is characterized by a certain conformation, where ferric ion is 
coordinated in the center of the three catechols of ENT. Thus, testing the ability of IroB 
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to glycosylate ENT in the presence of ferric iron provides valuable information about the 
conformation of ENT during catalysis. 
IroB-CH6 was exchanged into AAB2 buffer using NAP5 columns and the protein 
concentration was determined spectroscopically at 280 nm. The reaction was then set up 
according to the composition described in Table 5 and incubated for 1 h in bench top 
centrifugation device with a MWCO of 10 kDA at 25 °C.  After one hour the centrifugal 
device was centrifuged until no liquid was left in the top of the device. It was assumed 
that the ultrafiltration membrane retained all IroB-CH6 and the reaction was terminated 
by this step. The Fe-bound ENT is not retained during RP-HPLC separation and thus 
ferric iron has to be released prior to analysis. For consistency we acidified all samples 
with 0.5 µL of 4 M HCl to release ferric iron from ENT and analysed 80 µL of the 
supernatant using RP-HPLC in a ddH2O/ACN gradient acidified with 0.05% (v/v) TFA. 
The absorbance of ENT was followed at 330 nm. 
 
Table 5: Composition of the reaction mix for the activity assay to test the IroB activity in the 
presence of Fe
3+
 and in the absence of Mg
2+
.       
Component Control Presence of Fe
3+
 Absence of Mg
2+
 
MgSO4 500 µM 500 µM - 
FeCl3 - 200 µM - 
EDTA - - 200 µM 
UDP-glucose 600 µM 600 µM 600 µM 
ENT 100 µM 100 µM 100 µM 
IroB-CH6 (WT) 5 µM 5 µM 5 µM 





4.8 Structural integrity of IroB and mutants 
The structural integrity of IroB was assessed experimentally by far-UV circular 
dichroism, by thermal denaturation followed by far-UV circular dichroism, and by 
fluorescence spectroscopy.  
 
4.8.1 Far-UV circular dichroism 
Far-UV CD spectra of IroB were collected using a Jasco-815 spectropolarimeter 
equipped with a Peltier heating/cooling temperature control system. Spectra were 
recorded at 20 °C in the far-UV region from 260 nm to 200 nm. In detail, IroB-CH6 or 
mutants from freeze stock were thawed and adjusted to a concentration to 0.2 mg×mL
-1
 
with Dialysis Buffer based on the method described in Section 4.4. The sample was then 
loaded into a rectangular cell with 0.1 cm path length and spectra were recorded using the 
following parameters: sensitivity: standard (100 mdeg), data pitch: 0.2 nm, scanning 
mode: continuous, scanning speed: 20 nm×min
-1
, band width: 1 nm. For each 
measurement 5 scans were averaged. The final spectrum was corrected for buffer 
contributions, smoothed and converted to molar ellipticity using the integrated software 
package. Ultimately, the spectra were exported and plotted using OriginLab v8.6. 
 
4.8.2 Thermal denaturation 
Thermal denaturation was conducted in a Jasco-815 spectropolarimeter, where the same 
sample that was used in Section 4.8.1 was subjected to thermal denaturation by following 
the loss of signal at 222 nm with increasing temperature (20 °C to 98 °C). The parameters 
used were set as follows: data pitch: 0.2 °C, sensitivity: standard (100 mdeg), response 
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time: 16 s, band width: 1 nm, temperature slope: 30 °C×h
-1
. The spectrum was then 
normalized in terms fraction of folded protein at each temperature value by assigning the 
ellipticity value at 20 °C to 100% folded (fraction folded = 1) and the value at 60 °C to 
100% unfolded (fraction folded = 0). The melting temperature (Tm) was determined using 
the 1
st
 derivative function of the instrument’s software package, where the maximum 
between 20 °C and 60 °C determines the Tm.  
  
4.8.3 Fluorescence spectroscopy  
Fluorescence spectroscopy was used to assess the integrity of the tertiary structure of 
IroB-CH6 and mutants. Spectra were recorded at RT using a Varian Cary Eclipse 
spectrofluorimeter with the Scan Software version 1.1. Protein samples from freeze stock 
at -80 °C in Dialysis Buffer were thawed and the protein concentration was adjusted to 
0.05 O.D. in Dialysis Buffer at 280 nm. Then, 600 µL were transferred in a 1×1 cm 
Varian cuvette and spectra were recorded from 300 to 400 nm for the excitation 
wavelength of 280 nm and 295 nm for tryptophan/tyrosine and tryptophan emission, 
respectively. All spectra were recorded in CAT mode (average of 10 scans), excitation 
and emission slit width each set to 5 nm, the voltage and scan speed adjusted to 600 V 
and 600 nm×min
-1
, respectively. Spectra were then corrected for buffer contribution 
using the instrument’s calculation software, exported and analyzed using Origin software.   
 
4.9 Fluorescence based quenching assay 
A fluorescence-based quenching assay was used to determine binding affinity constants 
for ENT and IroB. IroB-CH6 and mutants were thawed and exchanged into FBQA Buffer 
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using a DG10 desalting column, which was equilibrated with FBQA Buffer prior to use. 
IroB-CH6 and mutants were exchanged according to the minimal dilution protocol 
supplied by the manufacturer. The protein concentration was determined 
spectroscopically (according to Section 4.4) and was diluted as fast as possible to a 
concentration of 100 nM and 600 µL were transferred to a 1×1 cm Varian fluorescence 
cuvette. The fluorescence was recorded using the simple read mode at an excitation 
wavelength of 280 nm and emission set to 340 nm with an averaging time of 5 s. The 
excitation and emission slit widths were set to 10 nm, and detector voltage was set to 
600 V. The initial fluorescence intensity of 100 nM IroB was always approximately 
100 arbitrary units under these settings. Upon titration of 2, 4, 6, 8, 10, 20, 30 and 40 µM 
ENT, dissolved in DMSO, the fluorescence intensity was measured and corrected for 
buffer contribution. Correction for inner filter effect was also performed using the 
following equation (1): 
 
            
         
                                                                                                                                                      
 
To obtain apparent equilibrium dissociation constants (KD’) an adapted equation based on 
(2) and (4) was as described in detail recently in van de Weert et al.  (103). The definition 
of the binding constant KD
’
 is shown in equation (2), where [P] and [L] are the free 
receptor and free ligand, respectively, and [PL] represents the complex of ligand and 
receptor.    
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By substitution of the free [P] with [P]tot – [PL] and the free [L] with [L]tot – [PL] we can 
rewrite equation (2) as follows: 
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By rearrangement and expansion of equation (3) we obtain through the intermediate steps 
(3b) and (3c) the quadratic equation (3d) in the form ax
2 
+ bx + c = 0. 
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Solving of the quadratic equation (3d) for [PA] using a standard solving formula for 
quadratic equations leads finally to equation (3e): 
 
[  ]  
     [ ]    [ ]      √     [ ]    [ ]        [ ]   [ ]   
 
                                                
 
The following formula (4) describes the assumption that that the fluorescence we observe 
F is a linear response depending on the fraction of protein in the bound state [PA]×[P]
-1
. 
Furthermore, it represents the assumption that the observed fluorescence F consists of 
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two components, where one is the free protein with F0 and the protein in complex with a 
ligand Fc. Equation (4) can be rearranged to obtain equation (4a).    
 
    [  
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]     [
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[ ]   
]                                                                                                                                   
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Ultimately, equation (3e) is used to substitute [PL] in equation (4a) and results in the 
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Data obtained in the fluorescence quenching experiment were imported into OriginLab 





The Results section is divided into three main parts: (i) the purification of IroB and 
variants including the establishment of an activity assay, (ii) the identification of the iroB 
gene product in E. coli Nissle 1917 and (iii) the investigation of the mechanism of IroB 
leading to the formation of the C-C bond observed during catalysis. In part (i) the final 
purity of IroB and variants was assessed using SDS-PAGE. Enzymatic activity was 
demonstrated in vitro using RP-HPLC to separate and identify conversion products 
arising from IroB activity. The probiotic, iroA-harbouring strain E. coli Nissle 1917 was 
used in part (ii) to identify the iroB gene product on transcriptional and translational 
levels using RNA and Western Blotting techniques, respectively. In part (iii), a homology 
model for IroB was generated. The model was used to identify residues potentially 
involved in catalysis. Such residues identified by our model were mutated, and the 
enzymatic activities of IroB variants were compared to that of IroB-CH6 (WT). In 
addition, wild type and IroB variants were characterized biophysically. Apparent 
equilibrium binding affinity constants (KD’) of ENT binding were determined in order to 
verify that the structural integrity of IroB each variant was maintained upon mutagenesis. 
  
5.1 Expression and purification of IroB and variants 
The purifications of IroB-CH6, IroB-NH6/TEV-373, IroB-NH6/TEV-389 and all variant 
proteins were carried out as described in the Methods. The purification scheme reported 
in the Methods section represents the final, optimized expression and purification 
procedure. In the course of this project the expression was optimized in terms inductor 
concentration and expression temperature and time to avoid the formation of inclusion 
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bodies and to maximize the yield of soluble IroB. The purification of IroB according to 
the published protocol in (43) led to heavy precipitation at high concentrations of protein. 
Thus, we optimized the purification protocol and tested the solubility in the presence of 
different stabilizers such as amino acids (e.g., L-arginine, L-tryptophan, L-tyrosine, and 
L-phenylalanine), osmolytes (e.g. glycerol, sucrose, glucose, trehalose), salts (e.g. KCl 
and NaCl) and by altering buffer pH. We observed that IroB undergoes conformational 
changes in the absence of stabilizers such as glycerol and sucrose, losing helical structure 
and adopting a conformation enriched in beta sheet as determined by far-UV circular 
dichroism (data not shown). This result suggests that unfolding followed by beta-sheet 
aggregation leads to precipitation of IroB. Ultimately, we maintained the structural 
integrity of IroB in the presence of glycerol (30-50% (v/v)) or 1 M sucrose or 1 M 
trehalose at pH 8.5 and low KCl concentrations of 25 mM with no visible precipitation 
even at relatively high protein concentrations up to 3 mg×mL
-1
.  The far-UV circular 
dichroism spectrum under these conditions was stable for at least 72 h. We decided on 
sucrose as our preferred stabilizer since it can be easily removed by dialysis or gel 
filtration, is less viscous than glycerol, and is the least expensive stabilizer.   
The final purification protocol yielded about 20 mg of IroB per liter culture. The final 
purity of WT IroB and variants after the final dialysis step of the purification procedure 
can be seen in Figure 12. In lane 1 and 9, the MWM is shown and the height of the 37 
kDa band is indicated. IroB-CH6 (MW: 42,498.6 Da) was loaded in lane 2 and 10, IroB-
NH6/TEV-373 and IroB-NH6/TEV-389 (MW: 42,572.6 Da and 44,586.0 Da) were 
loaded in lane 7 and 8, respectively, and in lane 3-6 and 11-16 all the variants are shown 
(MW: ~ 42,500 Da) that were purified over the course of this project. All of the purified 
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protein samples, except IroB-NH6/TEV-389, appear as a single dominant band above the 
37 kDa Marker band, consistent with the molecular weight calculated based on the 
primary amino acid sequence. The variant IroB-NH6/TEV-389 appears above the height 
of the 37 kDa band of the MWM as a doublet. 
 
Figure 12: SDS-PAGE (10%) stained with Blue Silver Coomassie-based stain. The upper panel shows 
an overloaded gel and broader separation range to demonstrate the overall purity of the sample and the 
lower panel more stringent range providing information for migration properties of different IroB mutants 
and variants.  In lane 1 and 9 the Kaleidoscope Molecular Weight Marker (MWM) was loaded and the 
height of the 37 kDa band was indicated. IroB-CH6 (lane 2 and 10), IroB-NH6/TEV-373, -389 (lane 7 and 
8) and all IroB variants (lane 3-6 and 11-16) were loaded. 
 
The migration properties of the upper band of this doublet is more consistent with the 
molecular weight calculated for this variant (44,586.0 Da), whereas the lower band is on 
the almost same height with the lighter IroB-NH6/TEV-373 (MW: 42,572.6 Da) 
suggesting that the upper band represents the full length IroB-NH6/TEV-389 and the 
lower band of the doublet a degradation product of the full-length protein. The purity of 
IroB-CH6 and variants is comparable and was estimated to be ≥85% based on 
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densitometry (data not shown). Purified IroB-CH6 and variants were stored as frozen 
beads at -80 °C. 
 
5.1.1 IroB enzymatic activity assay and product identity 
In order to provide evidence that IroB maintained its structure during the purification and 
storage procedure, an RP-HPLC activity assay was established to follow formation of 
MGE/DGE/TGE during IroB catalysis (see 4.7.1). Briefly, IroB was incubated in the 
presence of UDP-glucose, MgSO4, ENT and the supernatant was analyzed using a 
reversed phase (RP) column that was directly coupled to ESI/MS to confirm the identity 
of conversion products.   
 
Figure 13: RP-HPLC chromatogram showing the separation of ENT and MGE/DGE/TGE. The 
separation was conducted on a C18 resin and the absorption of ENT was followed at 330 nm. Supernatant 
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was analyzed after 5, 40 and 80 min of incubation in the presence of IroB and also in the absence of IroB 
(IroB
-
).    
 
The RP-HPLC chromatogram in Figure 13 shows the analysis of the reaction mixture at 
different incubation times upon addition of IroB after 5 min (black line), 40 min (red line) 
and 80 min (blue line) as well as a control reaction (IroB
-
) in the absence of IroB (pink 
line). The negative control IroB
-
 contains all the assay components (Mg
2+
, UDP-glucose 
and ENT) except IroB. The analysis of the negative control (pink line) shows a single 
peak with a retention time of 26.25 min representing ENT. No other major peaks are 
detectable in retention range from 20-27.5 min suggesting that ENT is the only 
compound of the reaction mix that binds to the RP-column. After incubation time of 
5 min (Figure 13, black line) in the presence of IroB, the peak representing ENT (26.25 
min) decreases significantly and a major peak with a retention time of 23.75 min along 
with a smaller peak with the retention time of 22 min appear, where the peak at 23.75 
min represents MGE and the peak at 22 min DGE. The reaction was the allowed to 
proceed for another 40 min (Figure 13, red line). The analysis after this incubation time 
reveals that substrate ENT (26.25 min) and MGE (23.75 min) were no longer detectable 
and the height of the peak representing DGE (22 min) significantly increased along with 
that of a new conversion product, namely TGE, represented by a new peak with a 
retention time of 20.75 min. An additional incubation of 40 min (T = 80 min; blue line) 
led to a decrease of the peak with retention time of 22 min (DGE) but no significant 
increase of the peak at 20.75 min (TGE).  
The analysis shows that the recombinant IroB used in these studies was properly folded 
and enzymatically active. It also established that IroB-catalyzed conversion of ENT to 
MGE/DGE/TGE can be followed using RP-HPLC. The compound ENT and its 
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conversion products can be efficiently separated by this technique based on the order 
hydrophobicity from ranging from ENT>MGE>DGE>TGE with ENT being the most 
hydrophobic molecule due to the lack of hydrophilic glycosyl groups. The conversion 
appears to be sequential with an initial build-up of MGE, which is then converted to 
DGE, and accumulation of DGE is followed by conversion to TGE. The conversion of 
ENT to DGE appears to occur relatively quickly (within 40 min) whereas the conversion 
from DGE to TGE is not completed after an additional 40 min, suggesting that 
triglycosylation is less rapid than mono- and diglycosylation.  
The RP-HPLC was directly coupled to ESI/MS to confirm the identity of the substrate 
ENT and the conversion products MGE/DGE/TGE. The results of the LC-MS analysis 
are shown in Table 6. 
  
Table 6: Summary of the LC-MS results to confirm the identity of the substrate ENT and the 

















ENT 670.6 670.2 26.25 
MGE 832.7 832.3 23.75 
DGE 994.8 994.4 22 
TGE 1156.9 1156.4 20.75 
1 
indicates the retention time under the applied conditions in RP-HPLC 
 
The result shows that there is good correspondence between expected and observed mass 
for substrate ENT and the enzymatic products of IroB (MGE/DGE/TGE) in the LC-MS 
analysis. These results clearly demonstrate that RP-HPLC is well suited to follow 




5.1.2 Activity in the presence of Fe3+ and absence of Mg2+  
The level of IroB activity in the presence of Fe
3+
 and in the absence of Mg
2+
 can provide 
valuable information about the conformation of ENT during catalysis and mechanistic 
requirement of IroB, respectively. In the presence of ferric iron the substrate ENT is fixed 
in a conformation, where the 3 catechol hydroxyls of ENT are involved in coordinating 
one ferric iron ion. In the iron-bound form, the DHB hydroxyl groups are not accessible 
for deprotonation by a potential base catalyst. A magnesium ion is often needed by 
glycosyltransferases of the GT-A fold to stabilize the negatively charged leaving group 
and glycosyltransferases of the GT-B fold often require a divalent metal ion for full 
activity. We therefore tested the ability of IroB to catalyse the glycosylation of ENT 
under three different conditions as shown in Figure 14. The control reaction contained 
Mg
2+ 
(black line), the -Mg
2+
 reaction (blue line) contained no Mg
2+
 but did contain 
EDTA to chelate any metal ion present in the reaction mix. And finally the reaction in the 
presence of Fe
3+




. The analysis shows that IroB in the 
presence of Mg
2+
 (Figure 14, black line) is able to convert ENT (retention time 36.25 
min) fully to DGE (retention time 31 min) and TGE (retention time 29.25 min). There are 
no significant amounts of other compounds detectable. However, in the absence of Mg
2+
 
(Figure 14, blue line) there is still significant amount of ENT (retention time 36.25 min) 
present in the supernatant after an incubation time that would have allowed the full 
conversion of ENT to DGE/TGE in the presence of Mg
2+
. The enzyme, though, was 
partially active in the absence of Mg
2+
 since a minor peak for MGE (retention time 33.5 
min) was detectable, suggesting that Mg
2+
 is required for full activity of IroB. In the 
presence of Fe
3+
 there is absolutely no conversion detectable (Fig. 14, red line) with only 
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the substrate ENT (retention time 36.25 min) being visible. This results shows that Fe-
loaded ENT is not a substrate for IroB. 
 
 
Figure 14: RP-HPLC chromatogram showing the conversion of ENT to MGE/DGE/DGE by IroB-
CH6 in the presence of Fe
3+
 and absence of Mg
2+
. The separation was conducted on a C18 resin and the 
absorption of ENT and conversion products was followed at 254 nm. The control reaction (Control, black 
line) contained Mg
2+
, but no Fe
3+









) is depicted in blue. 
 
5.2 Identification of iroB gene product in E. coli CFT073 
When examining the complete genome sequence of E. coli CFT073 (NCBI reference: 
NC_004431.1), one notices that the iroB gene (NCBI reference: NP_753168.1) is 
annotated with a length of 1164 bp, and a predicted protein product length of 387 aa. In 
contrast, in a recent in vitro characterization (43), iroB was cloned using an alternative 
start codon resulting in a protein product length of 371 aa (1113 bp) lacking 16 aa 
residues on the N-terminus. To assess the question which version naturally occurs in 
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iroA-harbouring E. coli we decided to identify the gene product in the iroA-harbouring, 
non-pathogenic E. coli strain Nissle 1917 on the transcriptional and translational levels. 
 
5.2.1 Identification of the iroB gene product on the transcriptional level 
In order to detect the iroB gene product on the transcriptional level, we cultivated E. coli 
Nissle 1917 under low iron conditions to induce the expression of genes involved in iron 
acquisition. These genes are located on the ent/fep-operon and iroA-cluster under control 
of Fur (Ferric Uptake Regulator). The Nissle 1917 cells were harvested and RNA was 
isolated, transcribed to cDNA using RT-PCR and finally amplified using PCR. In the last 
PCR step we had two reaction mixes, each using primer pairs that were either specific for 
gene products with lengths of 1164 bp (387 aa) or 1113 bp (371 aa). The primers for 
amplification contained also a 5’ overhang to introduce restriction sites that allow cloning 
of PCR products into a vector for sequencing. This 5’ overhang introduces 12 additional 
nucleotides into the PCR amplification products that were not considered when indicating 
the length of the PCR product length. The specificity of our primers was demonstrated 
using genomic DNA of E. coli (CFT073) as a template in a PCR reaction, where we 
applied the same PCR conditions as in the final PCR step to amplify iroB cDNA. The 
resulting PCR products were separated on an agarose gel (1% w/v) and DNA bands were 
detected in UV light after staining with SYBR Safe DNA gel stain (Figure 15). In lanes 4 
and 5 the products of the PCR amplification using genomic DNA from E. coli CFT073 as 
a template were identified between the 1 kb and 2 kb marker bands, consistent with the 
molecular weights expected after PCR amplification of products with lengths of 1164 bp 
and 1113 bp, respectively. The PCR product in lane 5 with an expected lengths of 1113 
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bp migrates closer to the 1 kb band found in lane 3 as the PCR product in lane 4 with an 
expected length of 1164 bp, consistent with the expected difference in length of this 
products of Δ=51 bp. In lane 1 there was no PCR product detectable after amplification 
of cDNA with the expected length of 1161 bp, implying that ‘long’ iroB mRNA, with a 
product length of 387 aa, does not occur in E. coli Nissle 1917.  
         
 
Figure 15: Agarose gel (1% w/v) stained with SYBR Safe DNA gel stain, followed by visualization of 
DNA bands in UV light at 332 nm. In lane 1 and 2 the PCR-amplification products using cDNA from 
E.coli Nissle 1917 as template were loaded, where in lane 1 a primer pair specific for the mRNA with a 
protein product length of 387 aa and in lane 2 a primer pair specific for the protein product length of 371 aa 
was used in the PCR reaction. Lane 3 shows the DNA molecular weight marker and lane 4 and 5 the 
positive control demonstrating the specificity of the primer pairs under the PCR conditions used in the 
reaction shown in lane 1 and 2, but using E.coli CFT073 gDNA as a template.  
 
On the contrary, an amplification product for cDNA with the expected length of 1113 bp 
was clearly detectable after amplification migrating on the same height as the 
corresponding positive control in lane 5. This implies that mRNA encoding IroB with a 




5.2.2 Identification of IroB gene product on translational level 
For the purpose of detecting IroB on the translational level in E. coli Nissle 1917, we 
overexpressed IroB-NH6/TEV-373 and IroB-NH6/TEV-389 in BL21 (DE3) and purified 
these proteins with an in-frame N-terminal hexahistidine tag. Both proteins contained a 
TEV protease cleavage site between the N-terminal hexahistidine tag and the start of the 
protein that could be used to remove the tag, resulting in proteins with lengths of 373 aa 
and 389 aa, respectively. Upon cleavage, additional two residues (GS) remained before 
the start methionine due to the nature of the cleavage site. These recombinant proteins 
were then used as standards to identify endogenous IroB using Western Blotting 
techniques with affinity-purified polyclonal anti-IroB antibody, allowing for the 
discrimination of proteins with lengths of either 371 aa or 387 aa in E. coli Nissle 1917 
lysate.  The lysate from E. coli AG1 cells were used as a negative control (iroA
-
). The 
resulting Western Blot is shown in Figure 16.     
 
Figure 16: Western Blot analysis to identify IroB gene product on the translational level. Detection 
was carried out using an IroB-specific affinity-purified polyclonal antibody. In lane 1 lysate of E. coli 
AG1 cells was loaded as a negative control (iroA
-
). Lane 2 shows the MW marker where the 37 kDa band 
is highlighted. In lane 3 and 4 recombinant IroB-NH6/TEV (373 aa) was loaded, where lane 3 shows IroB-
NH6/TEV before (-) and lane 4 after (+) cleavage with TEV protease. Lane 5 and 8 represents E. coli 
Nissle 1917 lysate. In lane 6 and 7 recombinant IroB-NH6/TEV with a length of 389 aa is loaded before (-) 
and after (+) cleavage with TEV protease. 
     
70 
 
Lane 1 contains proteins from E. coli AG1 (iroA
-
) lysate, indicating that there is no 
protein band visible around 37 kDa. This demonstrates that the polyclonal anti-IroB 
antibody is specific to IroB since it was not observed to bind to E. coli proteins of similar 
size to IroB. The non-cleaved recombinant IroB-NH6/TEV-373 in lane 3 migrates above 
the 37 kDa band of the MWM in lane 2. After adding TEV protease (lane 4), which 
removes the N-terminal hexahistidine tag and the linker region 
(MHHHHHHSSGRENLYFQ), the cleaved and the non-cleaved recombinant IroB-
NH6/TEV-373 bands were visible. The cleaved IroB-NH6/TEV-373 (calculated mass = 
40379.3 Da) migrates below the 37 kDa band of the MWM (lane 2). The migration 
distance of cleaved and non-cleaved IroB in lane 4 is in agreement with the expected 
difference in MW of Δ=2193.3 Da between cleaved and not cleaved IroB-NH6/TEV-373. 
The cleaved IroB-NH6/TEV-373 below the 37 kDa band of the MWM (lane 2) migrates 
to the same height as endogenous IroB that was detected in E. coli Nissle 1917 lysate 
(lane 5).  
The recombinant purified IroB-NH6/TEV-389 was loaded in lane 6 and was detected as a 
doublet, where one band migrated higher and one lower than non-cleaved IroB-
NH6/TEV-373 (lane 3). This observation suggests that the N-terminus is unstable and 
undergoes degradation. The upper band is presumably non-degraded full length IroB-
NH6/TEV-389 with a molecular weight of 44586.0 Da. After cleavage with TEV 
protease the doublet is still visible (lane 7), but the intensity of the upper band is 
significantly lowered. Furthermore, a band appears approximately at the same height as 
the 37 kDa band of the MWM (lane 2), representing cleaved IroB with a length of 389 aa 
and a calculated molecular weight of 42392.6 Da after removal of the hexahistidine and 
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linker region (MHHHHHHSSGRENLYFQ). The intensity of this band is weak and 
cannot account for the loss of intensity in the upper band of the doublet suggesting that 
the protein represented by the top-most band in lane 7 was further degraded during 
incubation with TEV protease. This is also supported by the fact that the intensity of the 
lower doublet band increased. The TEV cleaved IroB-NH6/TEV-389 migrates higher 
compared to the band representing endogenous IroB in the E.coli Nissle 1917 lysate in 
lane 8, suggesting that endogenous IroB of E.coli Nissle 1917 has a lower molecular 
weight and implying that the N-terminal sequence MRRLPDLDRQAERDFL of IroB-
NH6/TEV-389 is not present in endogenous IroB of E.coli Nissle 1917. Instead, 
endogenous IroB has a size consistent with IroB-NH6/TEV-373.  
For the remainder of the project, the IroB protein with a length of 371 aa was used for 
mutagenesis studies and biophysical characterizations. 
 
5.3 Identification of active site residues in IroB 
The next part of the thesis is divided into four subchapters (i) generating a homology 
model (ii) enzymatic activity of IroB-CH6 and variants (iii) biophysical characterization 
of IroB-CH6 and variants and finally (iv) determination of binding affinity constants for 
binding of ENT to IroB-CH6 and variants. 
   
5.3.1 Bioinformatic analysis 
The following results involve computational methods such as homology modelling, 
superposition approaches and sequence alignment to gain structural and functional 
information of IroB in the absence of any crystal structure.  
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5.3.1.1 Homology modelling 
In order to localize the IroB active site in the absence of any crystal structure, we used 
homology modelling to predict the three-dimensional structure of IroB. Homology 
modelling involves three steps: the identification of homologs that have been crystallized, 
model building, and evaluation of model structure. We initially identified crystallized 
homologs using the FFAS03 server (104-106) and HHpred server (107). The search 
algorithms of these alignment servers consider, besides the sequence identity, also 
structural features using profile hidden Markov models and are well established to detect 
homologues even below 20% sequence identity. Both servers identified the C-
glycosyltransferase UrdGT2 (PDB code: 2P6P) to be the best available homolog with a 
sequence identity between 22-23% suggesting that the structure of both proteins is 
similar. Thus, we used 2P6P as an input for Modeller v9.9 and used the integrated 
algorithm to align the primary amino acid of IroB and 2P6P resulting in the alignment 
shown in Figure 17, where identical residues are shaded in blue.     
 
Figure 17: Alignment of primary amino acid sequence of IroB and C-glycosyltransferase UrdGT2 
from Streptomyces fradiae (PDB code: 2P6P) as determined by Modeller v9.9 (85) and adapted in 




The two sequences aligned well over the whole length with an overall sequence identity 
of 24.74% as determined by Jalview and was then used for model building in Modeller 
v9.9. After model building using a standard Modeller v9.9 scheme that includes 
optimization by molecular dynamics, we obtained a model with a minimal DOPE 
(Discrete Optimized Protein Energy) score of -40909 and a good GA341=1 score (cut off 
≤ 0.7). The GA341 score indicates that the predicted fold is with ≥ 95% probability 
correct, where a fold is considered correct when 30% of the Cα carbons of target and 
template structure have an RMSD of ≤ 3.5 Å (108). The DOPE score is an atomic 
distance-dependent statistical potential model and is used to distinguish between ‘good’ 
and ‘bad’ models; here the following is applicable: the more negative the value, the better 
the model (109). We therefore selected this as our IroB homology model, and evaluated 
its predicted structure independently from Modeller v9.9 by superimposing the backbone 
of the IroB model and the template structure 2P6P using the software LSQMAN. In 
addition, we used web-based evaluation server VADAR and ProSA-web to assess the 
overall quality of our model. The superposition of the IroB model and the template 2P6P 
(Figure 18) shows an overall excellent structural alignment as determined by LSQMAN 
with an RMSD of 0.547 Å and a normalized RMSD (100) of 0.331 Å. These excellent 
RMSD values demonstrate that IroB can be modelled based on spatial restraints derived 
from 2P6P.  
The VADAR structural evaluation software suite generates an output file indicating the 
overall quality of the stereochemistry/packing quality and 3D profile quality index. Our 
IroB model was evaluated using the VADAR package, where it scored excellent overall. 
The Ramachandran analysis of phi/psi angles indicated showed that 93% of the residues 
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are found in the core region, 6% residues were detected in the allowed region, 1% of the 
residues are located in the generous and no residue was identified in the disallowed 
region. In comparison, 94% of the residues of the template structure 2P6P can be found 
in the core region and 3% of the residues in the allowed region. No residues were 
detected in the generous and disallowed region in 2P6P.     
 
 
Figure 18: Overlay of IroB model and the template structure 2P6P by LSQMAN. The model IroB is 
shown in red and the template 2P6P is shown in green. 
 
The ProSA-web server rated the IroB model with an overall excellent z-score of -8.57, 
which is well in the range of z-score determined from experimentally verified structures 
such as X-ray and NMR structures. The z-score of our template structure 2P6P, by 
comparison, was determined to be -10.98.  
The predicted structure of our IroB homology model exhibits a two-domain fold known 
as GT-B (Figure 19) with the N-terminal and C-terminal domain. Both domains possess a 
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similar architecture with parallel central beta-sheets packed in between alpha-helical 
structures.  
 
Figure 19: Cartoon 3D structure of IroB as predicted by Modeller v9.9 based on template 2P6P. 
Alpha-helical structures are shown in red, beta sheets in yellow and unordered structures in green. Figure 
was generated using PyMol (Schrödinger, LLC)  
 
A topology map of the IroB homology model was created with TopDraw (94) on the 
basis of its predicted 3D structure (Figure 20). The topology map of IroB demonstrates 
the two-domain fold with the N-terminal and C-terminal domains. Both domains possess 
6-7 central parallel beta-sheets (b1-7 and b8-13, respectively) that are surrounded by 
alpha helical structures (h1-13). The N- and C-terminal domains are connected by a long 
linker region. Ultimately, the C-terminal domain folds back to the N-terminal domain via 
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an envelope helix (h14 and h15). This type of fold is typical for nucleotide binding 
protein and known as a Rossmann-fold (110). 
       
 
Figure 20: Topology map based predicted 3D structure of IroB generated using TopDraw. N and C 
indicates the N-and C-terminus, beta-sheets are shown as arrow. Red arrows indicate that this beta sheet 
was predicted by Modeller v9.9 and beta sheets in grey are assumed. Alpha-helical structures are shown as 
cylinders, where light blue indicates helical structure above and dark blue below the plane of the central 
beta sheet core, respectively.   
 
5.3.1.2 Identification of active site in IroB model 
After confirming that we generated a high-quality homology model, we then used it to 
identify the glycosyl donor binding site, which was expected to be highly conserved 
among glycosyltransferases (as opposed to the acceptor binding site due to the variable 
nature of acceptor molecules across glycosyltransferases in nature). The server HHpred 
(107) was used to identify structures homologous to our IroB model. A high-scoring hit 
was that of CalG1 (3OTH), an O-glycosyltransferase from Micromonospora echinospora 
with an overall sequence identity of 28%. The crystal structure of CalG1 exhibited a GT-
B two-domain fold with Rossmann-like domains, similar to our predicted IroB structure. 
CalG1 was crystallized in the presence of TDP, an anologue of UDP, thus similar to the 
UDP-glucose co-substrate of IroB. Using LSQMAN, we therefore superimposed the 
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predicted IroB structure with TDP-bound CalG1 (3OTH) to predict the UDP-glucose 
binding site in IroB.  The overall RMSD of superposition of our IroB model onto the 
CalG1 structure was 1.547 Å and the normalized RMSD(100) was 0.987 Å. Figure 21 
shows the TDP binding site of 3OTH (A) and the predicted donor binding site of IroB (B) 
based on this superposition.   
   
 
Figure 21: Residue involved in TDP coordination in 3OTH (A) and superimposed glycosyl donor 
binding site of 3OTH and IroB model (B). TDP is shown with grey carbons in A and B. The side chains 
carbons and corresponding labels of 3OTH are coloured in blue (A). In picture B the glycosyl donor 
binding site of 3OTH and IroB were superimposed and the residues positioned suitable for UDP 
coordination in IroB are coloured with green carbons as well as the labels.    
 
The 3OTH binding site for TDP (Figure 21A) indicates the residues that are involved in 
coordination of the thymidine base, the pentose sugar ribose group and pyrophosphate 
group of TDP. Residue W279 is involved in a stacking interaction with the nucleotide 
base. Going in the C-terminal direction, W279 is followed by the hydrophobic residue 
V280 and then P281. The side chain of V280 possibly interacts with the hydrophobic side 
of the nucleotide base opposite to W279, and the amide oxygen of V280 acts as a 
hydrogen bond acceptor for thymidine. The residue P281 presumably plays a structural 
role. This is then followed by a Q282, a potential hydrogen bond acceptor that interacts 
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with the ribose moiety of TDP. The negatively charged pyrophosphate group appears to 
be interacting with a H295 and a very Gly-rich binding motif.  
The 3OTH binding site superimposes very well with the predicted glycosyl donor binding 
site of IroB (Figure 21B) and similar residues at equivalent locations can be found. 
Residue W264 in IroB is located at the same position as 3OTH W279, and can form a 
stacking interaction with the uridine base portion of UDP-glucose. At position 265 the 
hydrophobic residue Ile can be found, where in 3OTH a Val is located at the same 
position. I265 is well positioned to interact with the hydrophobic side of the nucleotide 
base, with the amide oxygen of this particular residue acting as a hydrogen bond 
acceptor. Proline at position 266 is well conserved (equivalent to 3OTH P281) and this 
residue could play a structural role by causing a turn that positions the following M267 to 
act a hydrogen bond acceptor for the pentose ribose sugar. The pyrophosphate group is 
stabilized by H280 (equivalent to 3OTH H295) and a Gly-rich motif, similar to the 
pyrophosphate-binding motif found in 3OTH.  
Our computational studies suggest that the glycosyl donor binding site is well conserved 
among these homologs and was modelled in IroB with high accuracy. The high level of 
conservation enabled us ultimately to model TDP in the binding site of IroB (Figure 22). 
The prediction of the TDP binding site in IroB reveals that the UDP-glucose binding site 
is located in the C-terminal domain of IroB and binds such that it is deeply buried in the 
interior of the protein and covered by the loop connecting b8 and h8 (Figure 20).  The 
binding motif 264-WIPM-267 (Figure 21B) interacts with the nucleotide base and 
pentose ribose sugar moieties of TDP and is located on the loop between b10 and h10, 
which then folds to the central b11 (Figure 20). Followed by this beta sheet the 280-
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HGGAG-284 motif (Figure 21B) is positioned such that it could interact with 
pyrophosphate group of TDP.  
 
Figure 22: Predicted 3D structure of IroB and TDP modelled in the glycosyl donor binding site. 
Helical structures are shown in red, beta sheets as an yellow arrow and unordered structure in green. 
Carbons of TDP are coloured in grey. 
 
Based on the position of TDP positioned into the IroB model, it can be presumed that the 
acceptor molecule ENT binds on the N-terminal domain close to the UDP-glucose 
pyrophosphate group in the cleft between the N- and C-terminal domains. Therefore, we 
identified residues in the vicinity of the pyrophosphate group of TDP that could be 
involved in binding of ENT (Figure 23). A very hydrophobic cluster consisting of Leu 
and Phe that could accommodate the hydrophobic catechol of ENT is marked with light 
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blue oval shape. Adjacent to this cluster the several potential base catalyst residues are 
located.  
 
Figure 23: predicted ENT binding site in IroB. Residues around the pyrophosphate group of TDP (grey 
carbons) are highlighted. The residues located in the predicted IroB binding site are illustrated with green 
carbons.  A hydrophobic cluster is highlighted in light blue.  
 
These residues include: D304, H134 and H138 and E60. Any of these residues could 
potentially be involved in proton abstraction during catalysis, whereas D304 and H134 
could also coordinate the glucose moiety of UDP-glucose.  
Furthermore our homology model predicts that the region in IroB between residues 
~60-70 is a long loop located proximal to the predicted binding site shown in Figure 23. 
This loop can possibly function as a “lid” that closes over ENT upon binding. We 
hypothesize that the loop could also contain catalytic residues. Potential base catalysts 
can be identified in this loop region, namely H65, H66 and E67. The identified residues 
located in the rigid ENT binding site and the mobile part adjacent to the binding site of 
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IroB represent promising targets for site directed mutagenesis studies. They were 
therefore mutated to gain insight in the role of these residues during IroB catalysis. 
 
5.3.1.3 Multiple Sequence Alignment (MSA) of IroB and homologs  
Multiple sequence alignment (MSA) was conducted with top hits of HHpred and IroB to 
gain more information about conserved motifs and structural features of IroB (Figure 24). 
The MSA was done using PSI-Coffee (97), a sequence alignment algorithm that 
considers also structural information in addition to the standard T-Coffee alignment 
procedure. Thus, the MSA tool was well suited for alignment of the rather distantly 
related sequences we were working with. The primary amino acid sequence of IroB 
(Figure 24, top) was aligned with the primary amino acids sequence of 11 different 
homologs with an averaged alignment score of 82 as determined by PSI-Coffee. As noted 
earlier IroB clearly features a fold with two similarly structured domains, where the N-
terminal domain (residues 1-190) is the acceptor (ENT) binding domain and C-terminal 
(residues 190-371) is the donor (UDP-glucose) binding domain. The first 50-55 residues 
of the N-terminal domain align very well and represent the core region of this Rossmann-
fold like domain. This conserved region is followed by a rather diverse region from 
residue 55-90 with respect to numbering of IroB and is boxed in black. This region 
corresponds to the h3-loop-h4 motif (see Figure 20) and was predicted to be the ENT 
binding site based on the predicted location of the pyrophosphate group of TDP in IroB 
(see Figure 23). The sequence diversity in this range possibly accounts for the variety of 









Figure 24: Multiple sequence alignment by PSI-COFFEE and further processed with Jalview of 
homologs detected by HHpred. Residues are shaded according to the degree of conservation from yellow 
to red. The conserved binding motif for the glycosyl donor is boxed in black. 2P6P: UrdGT2 from 
Streptomyces fradiae, 3IAA: CalG2 from Micromonospora echinospora, 2IYA: OleI from Streptomyces 
antibioticus, 3IA7: CalG4 from Micromonospora echinospora, 3H4T: chimeric protein engineered from 
GtfA (Amycolatopsis orientalis) and Orf1 (Actinoplanes teichomyceticus), 2IYF: OleD from Streptomyces 
antibioticus, 3OTG: CalG1 from Micromonospora echinospora,1RRV: GtfD from Amycolatopsis 
orientalis, 3OTI: CalG3 from Micromonospora echinospora, 3TSA: SpnG from Saccharopolyspora 
spinosa, 2C1Z: flavonoid glucosyltransferase from Vitis vinifera.  
 
The protein then folds back into the hydrophobic core of the N-terminal domain 
represented by a conserved region of very hydrophobic residues (IroB residues 102-130) 
and then crosses over to the C-terminal domain via the linker region from IroB residues 
180-200. There are several homologs such as 2C1Z or 2IYA causing large gaps in the 
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alignment before and within the linker region, suggesting that this region is highly 
variable in terms of loops connecting parallel beta sheets and the linker region itself. 
Ultimately, the C-terminal domain of IroB aligns very well overall between residues 200-
371, illustrating that the diversity in the donor binding domain is low, consistent with the 
similarity of glycosyl donor molecules used by glycosyltransferases. Remarkable are the 
regions from 264-267 and 280-284 and representing the highly conserved binding motif 
for glycosyl donor molecule that was identified in the IroB model and 3OTH (compare 
Figure 21, A and B). The sequence of 3OTH is also included in the multiple sequence 
alignment under the name 3OTG, which was crystallized in the absence of TDP. The 
alignment overall strongly supports the identity of the predicted acceptor and donor 
binding site in IroB due to high diversity and high conservation, respectively, expected 
for these binding sites. 
 
5.3.2 Comparison of enzymatic activities: IroB WT and variants  
Based on our homology modelling and bioinformatics analyses, we predicted that E60, 
E67, H134, H138 and D304 could act potentially as base catalysts during catalysis. We 
therefore individually mutated each of these residues to assess the effects of substitution 
on IroB enzymatic activity. Additionally, W264 was mutated to experimentally confirm 
that this residue is essential for UDP-glucose binding. Briefly, we incubated wild-type 
IroB-CH6 and variants under assay conditions and terminated the reaction after 1 h at 25 
°C by applying the reaction mix directly to the RP column. In contrast to the RP-HPLC 
analysis described in Section 5.1.1 we used a different column, which is the reason that 
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the retention times for ENT, MGE, DGE and TGE are shifted (17.0 min, 14.8 min, 13.25 
min and 12 min for ENT, MGE, DGE and TGE, respectively).  
We initially tested the activity of wild-type IroB-CH6 under assay conditions. The 
resulting chromatogram is shown in Figure 25. A major peak with a retention time of 
13.22 and a minor peak with a retention time of 11.97 min are visible representing DGE 
and TGE, respectively. There is almost no MGE (14.8 min retention time) and no ENT 
(retention time 17 min) detectable, suggesting that ENT and MGE were fully converted 
under these assay conditions. The integrated area of peaks between 10-20 min were 
determined using OriginLab v8.6 and the peak areas were measured, resulting in an area 
of 200.56 for DGE and 28.64 for TGE. This means that 100% ENT was converted to 
~12% TGE and 88% DGE.  
     
Next we mutated W264L, which is predicted to stack with the nucleobase of the glycosyl  
Figure 25: RP-HPLC chromatogram showing the conversion of ENT to MGE/DGE/DGE by 
IroB-CH6 The s paration was conducted on a C18 resin nd the absorption of ENT and conversion 
products was followed at 254 nm.   
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Next we mutated W264L, which was predicted on the basis of our model to stack with 
the nucleotide base of the glycosyl donor UDP-glucose (see Figure 21). The leucine 
substitution disrupts the ability to stack with the nucleotide base, but still maintains the 
hydrophobic character of the residue. We applied exactly the same assay conditions to 
W264L as for IroB-CH6, and analyzed the reaction mix for the presence of ENT and 
conversion products after allowing the enzymatic reaction to occur for  1 h at 25 °C. The 
resulting RP-HPLC chromatogram is shown in Figure 26.  The analysis shows the 
presence of three different compounds namely ENT, MGE and DGE represented by the 
peaks with the retention times of 17.0 min, 14.8 min and 13.2 min, respectively. The 
DGE peak is only minor with a relative abundance and an area of 28.98.  
   
Figure 26: RP-HPLC chromatogram showing the conversion of ENT to MGE/DGE/DGE by IroB-
CH6-W264L. The separation was conducted on a C18 resin and the absorption of ENT and conversion 




The peaks representing MGE and ENT have almost the same height and correspondingly 
the area as determined by OriginLab v8.6 is 124.90 for MGE and 123.24 for ENT. Taken 
together this result implies that 10% DGE, 45% MGE and 45% ENT are present and thus 
only 55% of the ENT was converted by W264L as opposed to 100% by IroB-CH6 
suggesting that the enzymatic activity is significantly reduced in W264L, consistent with 
our predicted role of this residue in nucleotide base stacking interaction. 
 
Figure 27: RP-HPLC chromatogram showing the conversion of ENT to MGE/DGE/DGE by IroB-
CH6-D304N. The separation was conducted on a C18 resin and the absorption of ENT and conversion 
products was followed at 254 nm. 
 
The residue D304 in IroB is highly conserved among glycosyltransferases (see Figure 24) 
and is thus an interesting candidate for mutagenesis. It is located on the C-terminal 
domain (glycosyl donor binding domain) and is well positioned to either coordinate the 
glycosyl moiety of UDP-glucose or act as base catalyst to activate a nucleophile during 
catalysis. We mutated D304 to asparagine to disrupt its ability to act as a base catalyst but 
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still maintain the ability to act as an isosteric hydrogen bond acceptor. Incubating D304N 
under assay conditions resulted in the RP-HPLC chromatogram illustrated in Figure 27.    
The analysis shows that after incubation period a single peak with the retention time of 
17.06 min can be detected, which corresponds to ENT. No conversion products can be 
identified, suggesting that D304 plays an important during catalysis. The area under the 
peak was determined to be 205.75; since no conversion products have been identified this 
value equates to 100% ENT. 
 
Figure 28: RP-HPLC chromatogram showing the conversion of ENT to MGE/DGE/DGE by IroB-
CH6-H134A. The separation was conducted on a C18 resin and the absorption of ENT and conversion 
products was followed at 254 nm. 
 
The residue H134 is located rather distant from the predicted ENT binding site. However, 
considering that some residue might be modelled incorrectly H134 is also a reasonable 
candidate to be a base catalyst. We therefore decided to mutate H134 to alanine, thus 
eliminating its ability to act as a base catalyst. The analysis of this mutant by our activity 
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assay resulted in the chromatogram shown in Figure 28. The analysis revealed three 
major peaks with a retention times of 13.4 min (DGE), 15.0 min (DGE) and 17.3 min 
(ENT). The retention time for all compounds is slightly shifted around 0.2 min to higher 
retention times, but the overall pattern is retained. The relative abundances based on peak 
areas were calculated to be: 7.6% (ENT), 29.4% (MGE) and 63% (DGE). This result 
suggests that the catalytic efficiency of H134A is slightly affected due to the introduced 
mutation.             
 
Figure 29: RP-HPLC chromatogram showing the conversion of ENT to MGE/DGE/DGE by IroB-
CH6-E67A. The separation was conducted on a C18 resin and the absorption of ENT and conversion 
products was followed at 254 nm. 
 
As discussed earlier, the loop located adjacent to the predicted ENT binding site (see 
Figure 20: h3-loop-h4) may possibly close over ENT upon binding and play a catalytic 
role. Therefore, we also identified IroB residue E67 as a possible base catalyst on this 
solvent-exposed loop. We mutated E67 to alanine and subjected this variant to our 
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activity assay. We obtained the RP-HPLC chromatogram shown in Figure 29. The 
chromatogram reveals two peaks typifying ENT (17.0 min) and MGE (14.8 min), where 
majority constitutes ENT. The calculated area for ENT is 150.93 and for MGE is 62.09, 
meaning that the relative abundance is 29.1% and 70.9% for MGE and ENT, 
respectively, demonstrating that the E67A mutation significantly reduces the catalytic 
activity of IroB. In addition we also prepared the following IroB variants: E60L, 
H65A/H66A, and H138L. We subjected these variants to our activity assay and 
calculated the relative abundance of ENT, MGE, DGE and TGE in the supernatant based 
on the RP-HPLC analysis (chromatogram not shown). The summary of all results with 
respect to the relative abundance of ENT/MGE/DGE/TGE of all our mutants is tabulated 
in Table 7.    
 
Table 7: Summary of relative abundances [%] of ENT/MGE/DGE/TGE after assaying IroB-CH6 
and variants. The results are derived from RP-HPLC chromatograms by peak integration. 
 Relative Abundance [%] 
 ENT MGE DGE TGE 
IroB-CH6 (WT) 0 0 88 12 
W264L 45 45 10 0 
D304N 100 0 0 0 
H134A 8 29 63 0 
H138L 0 0 100 0 
E60L 0 22 78 0 
H65A/H66A 8 60 32 0 
E67A 71 29 0 0 
 
The summary in Table 7 shows that IroB-CH6 (WT) is the most active enzyme, 
catalyzing the full conversion from ENT and MGE to mainly DGE and some TGE. The 
mutation W264L, predicted to be in the UDP-glucose binding site, renders IroB less 
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active, consistent with the predicted role of W264 to stack with the nucleotide base of 
UDP-glucose. Our studies demonstrate that IroB residue D304 plays an important role 
during catalysis. Substitution to asparagine cannot be tolerated at this position. This 
residue is predicted to either help coordinate the glucose moiety of the UDP-glucose 
donor, or to function as a base catalyst. The residues H134, H138 and E60 are located in 
the rigid part of the ENT binding site in IroB, as predicted on the basis of the homology 
model. The influence of mutations on these residues on catalysis is moderate, and 
conversion to large amount of DGE can still occur even though the rate appears to be 
lower, as seen for H134A. The residues located on the predicted mobile loop adjacent to 
the ENT binding site have a high impact on catalysis as seen for H65/H66 and E67. The 
double variant H65A/H66A is only able to convert 32% of ENT to DGE and for E67A 
there is no DGE detectable. However, H65A/H66A is still able to catalyse the formation 
of considerable amount of MGE (60%) and only a small amount of the substrate ENT is 
left. The variant E67A was also significantly impaired in its ability to catalyze the 
formation of MGE leaving most of the substrate ENT (71%) in its unglycosylated form. 
             
5.3.3 Biophysical characterization of IroB-CH6 and variants 
Biophysical characterizations were conducted to confirm that the overall structural 
integrity of variant IroB proteins was not disturbed due to the introduction of mutations in 
the primary amino acid sequence. To assess overall fold quality, we subjected IroB and 
variants several biophysical methods that are sensitive to secondary structure (far-UV 
circular dichroism), overall stability (thermal denaturation followed by far-UV circular 
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dichroism) and tertiary structure (fluorescence spectroscopy to probe the environment of 
intrinsic fluorophores (Tyr, Trp)). 
 
5.3.3.1 Far-UV Circular Dichroism 
Far-UV circular dichroism was used to gain information about the secondary structure 
content of IroB-CH6 and to compare it to mutants. The overall shape, intensity and 
characteristics of the CD spectra provide information regarding the relative abundance of 
distinct secondary structure elements such as beta-sheets, alpha helices and random coil. 
CD is thus well suited for studies comparing the structural qualities of IroB variants 
relative to the wild-type protein.  
We recorded CD spectra in the far-UV region from 260-200 nm at 25 °C in a 0.1 cm 
cuvette at 25 °C. IroB-CH6 and variants were directly taken from freeze stock measured 
in storage buffer containing 1 M sucrose and spectra were corrected for buffer 
contribution. We compared the CD-spectra of IroB-CH6 (WT), W264L, E67A and 
D304N and H65A/66A. Figure 30 shows the far-UV CD spectra of IroB-CH6 (WT) and 
selected variants. The spectrum of IroB-CH6 (WT) (black line) is typified by a positive 
band at around 200 nm. The minimum at 208-210 nm is skewed towards the 220 nm 
leading to a broadened minimum at 220 nm. At the 245 nm there is no absorption of 
circularly polarized light observed. The spectra of D304N (red line) displays similar 
characteristics of broad minimum at 220 nm and a positive ellipticity below ~203 nm. 
The spectra for E67A (blue line) and loop substitutions H65A/H66A (magenta line) show 
the same characteristics, with a positive band below ~203 nm and a broad minimum at 
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220 nm, suggesting that the mutations in the loop did alter the secondary structure 
content of IroB-CH6 (WT).  
 
Figure 30: Far-UV circular dichroism spectra of IroB-CH6 (WT) variants. IroB-CH6 (WT) (black 
line), D304N (red line), E67A (blue line), H65A/H66A (pink line) and W264L (green line) were analysed. 
The inlet illustrates the trend of voltage during CD measurement. 
 
The mutations D304N and W264L are located in the interior of the protein, where both 
induced minor changes in the properties of the CD spectrum. The mutant W264L (green 
line) shows similar characteristics as WT, with a slight variation in the 210-212 nm 
region. On the contrary, the mutant D304N possesses a less pronounced minimum at 
220 nm and the minimum in the 210 nm region is clearly visible and more pronounced, 
suggesting slight perturbation of the structure of IroB as a result of this mutation. In 
summary, the far-UV CD analysis shows that IroB-CH6 (WT) and variants are well 
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folded. The observed spectral differences are minor and should not be over-intrepreted. 
All of the proteins analyzed show comparable CD-signature indicating a α+β or α/β fold. 
       
5.3.3.2 Thermal denaturation 
Thermal denaturation was performed to assess the overall thermal stability of IroB-CH6 
(WT) and variants, and to test if protein stability was affected by mutations. The thermal 





Figure 31: Thermal denaturation followed by far-UV circular dichroism spectroscopy at 222 nm 
shown as percent folded between 20 °C and 60 °C. Transitions of IroB-CH6 (WT) (black line), E67A 
(red line), D304N (blue line), H65A/H66A (pink line) and W264L (green line) are illustrated. 
 
The raw thermal denaturation curves (data not shown) showed a transition at around 
40 °C and a loss of about 40% of the signal intensity over the course of this transition, 
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followed by a stable signal at 60 °C - 85 °C. In a few cases a second transition occurred 
at around 85 °C, however, this transition was not included in the analysis, because a 
stable plateau was not achieved when raising the temperature to the maximum of ~95 °C. 
Therefore, the stable signal at 60 °C (60% of the initial CD signal) was assumed to be 0% 
folded (100% unfolded) and the denaturation curves were normalized accordingly and 
plotted using OriginLab v8.6 (Figure 31). The data shows that the mid-point of the 
transition from 100% folded to 0% folded I located for IroB-CH6 (WT) at around 37 °C 
(black line). The mid-point of transition is the nearly the same for all mutants suggesting 
that they have stabilities similar to the wild-type protein, and that the overall fold is not 
affected by these mutations. To determine the exact mid-point, 1
st
 derivatives of the 
melting curves were calculated, where the maximum of the 1
st
 derivative indicated the 
inflection point and therefore the melting temperature (Tm). The results are summarized 
in Table 8 showing that all Tm values are centred around 37 °C, thus demonstrating that 
the mutations did not alter thermal stability of IroB.  
  
Table 8: Summary of Tm values of IroB-CH6 (WT) and variants. Values were determined using the 
maximum between 20 °C and 60 °C of the 1
st
 derivative.  
 Tm [°C] 









5.3.3.3 Fluorescence spectroscopy 
The excitation and emission properties of fluorophores such as tryptophan are highly 
dependent on their environment and are thus sensitive to environmental changes. By the 
means of fluorescence spectroscopy, the integrity of the tertiary structure of IroB-CH6 
(WT) and mutants were probed. 
The protein concentration of IroB-CH6 (WT) and mutants was adjusted such that the 
absorbance at 280 nm was below 0.05 O.D. to avoid inner filter effects. The emission of 
the intrinsic fluorescence was measured from 300-400 nm after excitation of the sample 
at 280 and 295 nm. We first probed variant W264L for any significant changes in the 
tertiary structure by comparing its emission spectra to IroB-CH6 (WT) (Figure 32). 
 
Figure 32: Fluorescence spectra of IroB-CH6 (WT) and W264L. The emission spectrum of IroB-CH6 
(WT) after excitation at 280 nm and 295 nm is displayed in blue and black, respectively. The emission 




The emission spectrum of IroB-CH6 (WT) after excitation at 280 nm (blue line) exhibits 
a higher intensity as after excitation at 295 nm accounting for the fact that the excitation 
wavelength of 295 nm specifically excites tryptophan, whereas at 280 nm both, 
tryptophan and tyrosine are excited (black line). The maximum emission of both spectra 
is at 345 nm. This maximum represents the red end of emission spectrum of tryptophan 
and tyrosine, thus implying that the eight tryptophan residues in IroB-CH6 (WT) are 
relatively solvent-exposed and located in a more polar environment. Interestingly, 
mutating one of the eight tryptophans to a leucine did not decrease the overall intensity 
significantly (red and pink line), even though the number of protein molecules used was 
constant as determined by UV/VIS spectroscopy using the corresponding molar 
extinction coefficient. However, a slight blue shift is detectable in both spectra for 
W264L (red and pink) with respect to IroB-CH6 (WT). Since the emission peak of 
tryptophan is solvatochromic, a blue shift indicates that W264, mutated to a leucine in 
W264L, was located in a more polar environment on the surface of IroB, contributing 
significantly to the red-shifted emission spectrum of IroB-CH6 (WT). In conclusion, such 
as shift is expected when mutating tryptophan and does not necessarily implicate a 
disturbance of the overall tertiary structure. 
In Figure 33 the fluorescence spectrum of IroB-CH6 (WT) in comparison with those of 
the IroB variants D304N, E67A and H65A/H66A after excitation at 280 nm and 295 nm 
is shown. All spectra overlap very well with a maximum emission at ~345 nm. No 
solvatochromic shifts were detectable, demonstrating that the tertiary structures of these 
variant proteins, as reflected here by fluorophore environements, were not significantly 




Figure 33: Fluorescence spectrum of IroB-CH6 (WT) and various mutants. The legend indicates the 
colour the emission spectrum is displayed in, the name of the mutants and in brackets the excitation 
wavelength. 
 
5.3.3.4 Determining Binding Affinity Constants 
In order to determine apparent binding affinity constants (KD
’
) of IroB to ENT, we used a 
quenching assay that was originally developed by Lin et al. for the same purpose (82). 
Briefly, the initial fluorescence intensity of IroB was measured, which is represented as 
F0. The emission spectrum of intrinsic IroB fluorescence and the excitation spectrum of 
ENT possess substantial overlap. Thus, IroB can act as a FRET donor and transfer 
excitation energy to the FRET acceptor ENT. Fluorescence resonance energy transfer 
(FRET) is only possible if donor and acceptor are in close proximity, as it occurs during a 
binding event. This phenomenon leads to a concentration-dependent apparent quenching 
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effect of intrinsic IroB fluorescence by bound ENT that can be used to determine 
apparent binding affinity constants (KD’). 
 
Figure 34: Plot of F/F0 vs. ENT concentration and determination of binding affinity constants by 
fitting the data to equation (5).  
 
The plot of F/F0 vs. ENT concentration (Figure 34) resulted in a binding curve that 
converged against ~30% of the initial fluorescence, suggesting that several tryptophan 
residues are proximal to the ENT binding site in IroB. The data fitted well to equation (5) 
with high R
2
 value of 0.99, the apparent KD value derived was 2.8 µM with an error of 
the fitting of 0.1 µM. The determination of the apparent KD was performed twice 
independently and resulted in similar apparent KD values. The apparent KD values were 
also determined for a number of the variants studied in this project using the same 
method. The determined values are summarized in Table 9. The binding assay for each 
mutant was performed twice and resulted always in similar values. The apparent KD 
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values were all found to be on the same order of magnitude suggesting that all mutants 
were still able to bind ENT with high affinity.  These binding data therefore provide an 
independent confirmation of fold preservation in the IroB variants examined. 
 
Table 9: Apparent KD values derived from fluorescence based quenching assay tabulated for selected 
mutants.  
 KD [µM] 
IroB-CH6 (WT) 2.8 ± 0.1
1
 
W264L 4.5 ± 0.3
1
 
D304N 9.1 ± 0.6
1
 
E67A 4.8 ± 0.2
1
 







The Discussion is structured in a manner parallel to the Results Section: 
expression/purification, identification of the natural IroB gene product, and identification 
of IroB active site catalytic residues. 
 
6.1 Expression/purification of IroB 
The expression and purification of IroB was constraint by the high tendency to form 
insoluble inclusion bodies and also the insolubility of IroB at concentrations above 
~0.3 mg×mL
-1
 during purification. To address the problem of the inclusion body 
formation, we lowered the expression temperature and decreased the inductor 
concentration to avoid the formation of insoluble aggregates during expression. The 
formation of inclusion bodies during overexpression is based on the aggregation of 
folding intermediate exposing hydrophobic patches (111). By lowering the temperature 
and inductor concentration to 20 °C and 400 µM, respectively, the yield of soluble IroB 
significantly increased presumably because IroB had more time to mature (111). 
However, an estimated 90% of IroB was still found in the insoluble fraction, supporting 
the notion that IroB is a slow-folding protein or/and IroB forms aggregates even in the 
folded state at high concentrations in vivo. IroB is a protein that naturally occurs in E. coli 
(CFT073). Therefore the expression strain E. coli BL21 (DE3) should be a good host and 
should provide a good environment to allow proper folding of IroB in terms of a reducing 
environment, chaperones, pH and ionic strength. 
The second problem, the tendency to precipitate during purification, was addressed by 
optimization of various parameters such as ionic strength, pH, and additives known to 
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stabilize proteins conformationally (e.g., glycerol) or shield hydrophobic regions of 
proteins (e.g., L-arginine) (112). IroB was most soluble at a relatively high pH (8.5) and 
low salt concentration (25 mM). The combination of high pH and low salt could be 
beneficial due to the repelling overall negative charge of IroB at this pH, which is 
minimally shielded at low salt concentrations (113). More important, however, was the 
role played by osmolytes during purification. Not only the solubility was greatly 
improved in the presence of 30-50% (v/v) glycerol, 1 M trehalose and 1 M sucrose, but 
also conformational stability as determined by far-UV circular dichroism. Far-UV 
circular dichroism showed that IroB underwent conformational changes such as loss of 
alpha helical structure and a gain in beta sheet structures (data not shown) shortly after 
exchanging IroB in buffer without any osmolytes. Accompanied with the observation that 
IroB precipitates heavily at higher concentrations under these conditions, we concluded 
that partial unfolding followed by beta sheet aggregation could be responsible for the low 
solubility.  
Osmolytes can be classified as stabilizing and destabilizing. Stabilizing osmolytes are 
preferentially excluded from the protein backbone (e.g., glycerol, sucrose) and 
destabilizing accumulates at the backbone (e.g., urea, GdmCl), resulting in an 
unfavourable interaction of stabilizing osmolytes with the unfolded state as (114, 115). 
Interestingly, the synthesis of osmolytes (e.g., glycerol, trehalose) is induced in vivo 
under stress to protect proteins from denaturation (116). The fact that osmolytes had an 
especially beneficial effect on IroB stability and solubility further supports the notion that 
IroB is intrinsically conformationally unstable. The stabilizing effect of osmolytes is 
dependent on the polar surface area of the osmolyte – the smaller the fractional polar 
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surface area, the more stabilizing. The fractional polar surface area of trimethylamine N-
oxide (TMAO) is significantly smaller compared to sucrose, trehalose and glycerol and 
could therefore be beneficial with regard to future experiments (114). Ultimately, we 
decided to use sucrose as a stabilizer, since it can be easily removed by gel filtration, and 
is commercially available for a low price. Once the constraints regarding solubility were 
addressed, IroB was able to be expressed, purified and stored in large amounts. 
  
6.1.1 IroB enzymatic activity assay and product identity  
To prove that IroB is enzymatically active and thus properly folded after expression, 
purification and storage, we tested the ability of IroB to catalyse the formation of 
MGE/DGE/TGE in vitro using the strategy previously published by Fischbach et al., 
where they detected products arising from IroB activity by LC-MS (43). We used a 
relatively high concentration of IroB (5 µM) to achieve fast product formation and 
observe all possible products including TGE (Figure 13). After 5-min incubation in the 
presence of IroB we observed almost full conversion of ENT to MGE and only minor 
peaks representing DGE and ENT. The conversion appears sequential, since we initially 
observe accumulation of MGE. We allowed the reaction to proceed for additional 40 min 
and detected no more ENT and MGE, but approximately equal amounts of DGE and 
TGE. Additional 40 min incubation led to a decrease of the peak representing DGE, but 
no increasing amount of TGE.  The successive conversion of ENT to first MGE and then 
MGE to DGE was also observed by Fischbach et al. (43). This could be an indication that 
IroB has different affinities for ENT and glycosylated derivatives of the order 
ENT<MGE<DGE<TGE, where the affinities are lowered through the additional bulk of 
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the glucose moieties attached to the catechol of ENT. This hypothesis could be easily 
tested using the fluorescence-based binding assay to determine KD’ with enzymatically 
prepared and purified MGE/DGE/TGE used as ligands instead of ENT.  
Direct comparison of the enzyme activity of our recombinant IroB with published 
information on IroB (43) was not possible. Steady-state enzyme kinetics data has to be 
obtained for this purpose. However, such experiments proved to not be straightforward 
since ENT has a lower stability at physiologically relevant temperatures (t1/2 = 30 min at 
37 °C in Tris buffer at pH 8 (19)). This instability of the ENT substrate could be reason 
for the observed decrease in the amount in DGE with no increase in TGE upon HPLC 
separation after 80 min incubation (Figure 13). Qualitative analysis of the chromatogram 
in Figure 13 supports the hypothesis that the initial glycosylation reactions leading to 
MGE/DGE formation are catalysed with higher efficiency compared to the third 
glycosylation to produce TGE. This conclusion is drawn on the basis that almost full 
conversion to MGE is catalysed within 5 min, and full conversion to DGE is achieved 
some time before 45 min, as opposed to the time period between 45 min and 80 min, in 
which only minor decrease of the amount of DGE was detected and no more 
accumulation of TGE. Higher catalytic efficiencies for the first and second glycosylation 
steps have also been described by Fischbach et al. (43). These in vitro observations 
correlate very well with in vivo data demonstrating a high abundance of DGE in the 
supernatant of iroA-harbouring Salmonella enterica  (41). However, a final conclusion on 
that matter cannot be drawn owing to the qualitative data, and also the effect of protein 
precipitation over time course of the assay cannot yet be excluded.    
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Fischbach et al. always included 5 mM MgCl2 in their reaction mix during their in vitro 
characterizations of IroB, although never commented if a divalent metal ion is actually 
required (43). We therefore tested the activity of IroB in the presence and absence of 
Mg
2+
 and additionally supplemented our Mg
2+
 minus control with EDTA to chelate any 
metal ion present in our buffer or already bound to IroB. Furthermore, we tested the 
ability IroB to catalyse the glycosylation reaction in the presence of Fe
3+
, thus fixing 
ENT in the defined iron-binding mode, where 2,3-OH of the three DHB subunits of ENT 
can hexacoordinate one ferric ion in an octahedral geometry (21). Analysing the resulting 
chromatogram revealed that the catalytic activity of IroB is significantly reduced in the 
absence of Mg
2+
 with only minor formation of MGE. This is in contrast to the positive 
control in the presence of Mg
2+
 where full conversion of ENT and MGE to DGE and 
TGE was observed under the same conditions. In the presence of Fe
3+
 no conversion to 
MGE/DGE/TGE was detectable under assay conditions.  
The drastically reduced catalytic activity in the absence of Mg
2+
 was at first surprising to 
us. IroB was predicted to adopt a GT-B fold (www.cazy.org) and glycosyltransferases of 
that fold type usually do not require a divalent metal, since they stabilize the 
pyrophosphate leaving group during the SN2 mechanism by helix dipole interaction or 
positively charged amino acid side chains (63, 117). In addition, the typical DXD metal-
binding motif observed in metal-dependent GT-A is not present in IroB (50). However, it 
has been reported that most glycosyltransferases need a divalent metal ion for full activity 
except for GtfB (50, 57, 118). Interestingly, the β-Glucosyltransferase from phage T4 was 
crystallized in the presence of UDP and the full donor substrate UDP-glucose. Only in 
the UDP-bound form was a divalent metal ion found at the position where the glucose 
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moiety was located before. Therefore they assumed that the metal ion could play a role in 
product release rather than leaving group departure (71). Since IroB is still active in the 
presence of EDTA and the absence of Mg
2+
 this role of the metal ion can also be 
proposed.  
The incapability of IroB to catalyse the glycosylation of holo-ENT (e.g., ferric-ENT) has 
previously demonstrated by Lin et al. and could be confirmed by our experimental 
approach (Figure 14). The authors attributed this observation to the inaccessibility of the 
ENT catechol hydroxyls for binding to IroB (82). Noteworthy in this context, are the 
distinct physical and steric properties of apo-ENT (net charge: neutral) and holo-ENT 
(net charge: -3; fixed conformation with hydroxyl groups of catechols coordinating one 
iron ion) (32).  The calyx of NGAL for holo-ENT, for example, is adapted to these 
distinct properties, and binding is mediated by NGAL positively charged side chains 
(lysine/arginine) based on cation-π and electrostatic interaction. Furthermore, the calyx of 
NGAL allows distinct binding of all three catechol groups of ENT (30, 32). Neither 
positively charged side chains nor distinct binding pockets for catechol subunits are 
found in IroB model (Figure 23), suggesting completely different binding modes for 
holo- and apo-ENT based on steric and physical properties. Regrettably, the approach to 
measure the apparent equilibrium binding affinity constant of holo-ENT and IroB was not 
successful, because of heavy precipitation of IroB in the presence of Fe
3+
 and also 
because of quenching of intrinsic IroB fluorescence by Fe
3+ 
(data not shown). In 
conclusion, the notion that the hydroxyl group of the DHB subunit might be recognized 
by IroB is oversimplified, because the steric and physical differences between holo- and 
apo-ENT are significant and could simply prevent holo-ENT from being recognized by 
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IroB, independent from hydroxyl groups of DHB. Therefore, this interpretation is rather 
limited and allows only the conclusion that holo-ENT is not a substrate of IroB. 
 
6.2 Identification of iroB gene product on the transcriptional and the translational 
level in Nissle 1917 
As discussed in the previous section, when IroB was expressed according to Fischbach et 
al. (43) with a length of 371 aa (without linker and affinity tag),  it appeared 
conformationally unstable during expression and purification. Interestingly, the iroB gene 
in E. coli CFT073 (NCBI reference: NP_753168.1) is annotated with 387 aa and contains 
additional N-terminal aa (MRRLPDLDRQAERDFL). Therefore, to exclude the 
possibility that these additional N-terminal aa are necessary for the conformational 
integrity of IroB, we identified the natural iroB gene product in E. coli Nissle 1917 on the 
transcriptional and the translational level. The probiotic, non-pathogenic strain E. coli 
Nissle 1917 (DSM6601) harbours the iroA gene cluster on the Genomic Island I (83). 
This region is fully sequenced and deposited under code AJ586887.1 in GenBank 
(http://www.ncbi.nlm.nih.gov). The iroA locus of Nissle 1917 on Genomic Island I 
(AJ586887.1) and E. coli CFT073 (NC_004431.1) were compared using BLAST 
(http://www.ncbi.nlm.nih.gov). The comparison clearly demonstrated that up- and 
downstream, as well as the iroB nucleotide sequence itself is identical (data not shown). 
Thus, E. coli Nissle 1917 is well suited to identify the iroB gene product in CFT073. 
Firstly, we analyzed the upstream sequence of the iroB gene to identify regulatory 
elements such as the translation initiation Shine-Dalgarno (SD) sequence. For optimal 
gene expression the SD sequence must provide good base pairing abilities with the anti-
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SD sequence of 16S rRNA and must be located 8-10 base pairs upstream of start codon 
(119). Indeed, we found an optimally-spaced subsequence (GAGG) 10 bp upstream of 
the start codon coding for IroB with a length of 371 aa that could represent a potential 
degenerated SD core sequence (GGAGG) similar to what is usually found in E. coli 
(119). In contrast, no such sequence was found upstream of the start codon coding for 
IroB with a length of 387 aa. Additional information provides the start codon itself. The 
start codon of IroB (371 aa) is a strong ATG, whereas the start codon of IroB (387 aa) is 
a weak GTG. To compensate for a weak start codon one would expect a strong SD 
sequence (119). Therefore, IroB (371 aa) is more likely the gene product of iroB since it 
possesses the common ATG start codon and a SD sequence. 
To ultimately exclude the possibility of the existence of IroB (387 aa), we identified the 
iroB gene product on the transcriptional level. Here we cultivated E. coli Nissle 1917 
cells under iron starvation to induce Fur regulated genes. We then isolated whole RNA 
and transcribed mRNA for IroB to cDNA using a specific primer for IroB. The cDNA 
was amplified using specific primer pairs for IroB (371 aa) and IroB (387 aa), 
respectively. By this approach, we were only able to prove the existence for mRNA for 
IroB (371 aa), but not the existence of mRNA for IroB (387 aa).  Nevertheless, we also 
identified IroB on translational level. We cloned expression constructs for IroB (371 aa 
and 387 aa) with TEV cleavable affinity tag. The second residues in either IroB (371 aa) 
and IroB (387 aa) is arginine, therefore the N-terminal methionine is not excised by 
methionine aminopeptidase and was included in all our constructs (120). After cleavage 
of the expressed proteins, they would only differ by an additional GS sequence due to the 
nature of TEV cleavage. Subsequently referred as IroB (373 aa and 389 aa), these 
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recombinant proteins were used for direct comparison with endogenous IroB from Nissle 
1917 by SDS-PAGE followed by Western Blotting. Our results (Figure 16) showed that 
recombinant IroB (373 aa) is similar in MW as endogenous IroB (Nissle 1917), whereas 
the MW of IroB (389 aa) is significantly larger. Thus, we assume that IroB (371 aa) is the 
iroB gene product on translational level. Interestingly, IroB (389 aa) was prone to 
degradation in contrast to IroB (373 aa), indicating that the N-terminal sequence 
(MRRLPDLDRQAERDFL) is solvent exposed and flexible, providing further support 
that this sequence is not part of an IroB fold. 
In summary, the bioinformatic analysis of the iroB gene sequence, as well as our 
experimental data clearly demonstrates that IroB (371 aa) is naturally expressed in iroA-
harbouring E. coli strains such as Nissle 1917 and CFT073 and that the version of IroB 
with 387 aa in NP_753168.1 is likely an annotation error.  
 
6.3 Identification of active site residues in IroB 
The overall major objective of this project was to establish a homology model as 
structural framework to allow formulation and testing of mechanistic hypotheses for the 
glycosylation of ENT. The only available, experimentally determined, three dimensional 
structure of a C-glycosyltransferase, UrdGT2 (PDB code: 2P6P), proved to be well suited 
for this purpose. It allowed us to generate a homology model based on 24% sequence 
identity that passed all bioinformatics-based evaluation tests. Superposition of the IroB 
model with CalG2 (PDB code: 3OTH) furthermore allowed us to identify the conserved 
UDP-glucose (donor) binding site and provided us in addition with valuable information 
about location and identity of residues in the ENT (acceptor) binding site. 
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In the following sections the role of several residues involved in either UDP-glucose 
binding or residues located in the ENT binding site will be discussed. Relevant residues 
that were elucidated during these studies will be discussed individually taking into 
account all available information from the Results section, such as multiple sequence 
alignment, biophysical characterizations and apparent binding affinity constants. After 
that, a potential mechanism for the glycosylation of ENT will be suggested based on the 
information revealed by site directed mutagenesis and the current state our research into 
this protein.    
            
6.3.1 W264 – π-stacking interaction with uridine 
W264 is part of the well conserved 264-WIPM-267 binding (see Figure 24) motif located 
between b10 and h10 (see Figure 20) that interacts with nucleotide base and the ribose 
moiety. The W264 residue is predicted to interact with the nucleotide base by a stacking 
interaction (Figure 21, B). The W264L variant showed reduced activity and was only 
able to convert 45% of ENT to MGE and 10% DGE (Table 7). Biophysical 
characterization using far-UV circular dichroism revealed W264L is well folded and the 
structure is not significantly disturbed compared to wild-type IroB. Fluorescence 
spectroscopy showed a slight blue shift compared wild-type IroB showing that W264 is 
solvent exposed. The apparent equilibrium binding affinity constant was determined to be 
KD’= 4.5 µM. The intention to mutate W264L was to experimentally verify the prediction 
that W264 interacts indeed with the nucleotide base as revealed by our homology model. 
We observed significantly reduced activity. The variant, however, was still able to bind 
ENT with affinity comparable to wild-type IroB. Therefore, we assume that the ability to 
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bind UDP-glucose is impaired by this mutation, which is in accordance with our 
prediction. 
The observation that TDP is covered by a loop (Figure 22) implies that the loop 
connecting b8 and h8 exists in an “open” conformation to accept the glycosyl donor and a 
“closed” conformation once the donor is bound. The residue W264 is located on this 
mobile loop in the IroB model, and interacts presumably via π-stacking with the 
nucleotide base once the loop is in its “closed” conformation. This mode of binding is 
well conserved and has been described for various other glycosyltransferases such as 
GTf3 (121), VvGT1 (122) and the CalG1-4 family (123) and was suggested to protect the 
UDP-glucose against hydrolysis (57). It is notable that the crystal structures of CalG1-4 
in the presence of TDP demonstrate how the binding motif 264-WIPM-267 might interact 
with TDP, the UDP-analog. The Trp residue interacts via π-stacking with the nucleotide 
base, as predicted in our IroB homology model. Based on the interaction of the binding 
motif 279-WVPQ-282 in CalG1, the IroB motif 265-WIPM-267 might predominantly 
interact with uridine and ribose moieties by hydrogen bonding of amide oxygen and 
nitrogen of the backbone. The 295-HGGSG-299 motif in CalG1 interacts similarly with 
α- and β-phosphate group via hydrogen bonding (123).  Since this motif is also well 
conserved in IroB (see Figure 24) the same role can be predicted for 280-HGGAG-284.  
In summary, we achieved our goal by showing that W264 is indeed involved in uridine 
coordination, thus experimentally confirming the accuracy of our homology model. In 
addition, the UDP analogue TDP could be modelled in the IroB active site and showed 
essentially the same interactions of well conserved motifs with TDP as shown in 
experimentally determined three dimensional structures such as CalG1-4. It is remarkable 
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that none of these structures served as template for homology modelling of IroB, 
demonstrating the high degree of conservation of the structural framework for TDP/UDP 
coordination. 
 
6.3.2 D304 – coordination of the sugar donor moiety     
D304 is located on the C-terminal donor-binding domain on N-terminus of helix h12 (see 
Figure 20). It is positioned on the interface between the N- and C-terminal domains, 
where it could participate in coordinating glucose moiety of UDP-glucose, or act as a 
base catalyst to abstract protons from ENT catechol that is bound in the N-terminal 
domain. Furthermore, D304 is part of D/E motif that is highly conserved among 
homologues (see Figure 24 (black box)). We mutated D304 to an asparagine, which 
completely abolished detectable glycosylation activity under our assay conditions – no 
MGE/DGE/TGE at all was identified. However, the variant D304N was well folded and 
the thermal stability was comparable to wild-type IroB as determined by far-UV circular 
dichroism. Also the tertiary structure was not significantly disturbed according to 
fluorescence emission; no change in the environment of Trp was detectable (Figure 33). 
Most importantly, this mutant was still able to bind ENT with an apparent KD’ on the 
same order of magnitude with wild-type IroB (9.1 µM as compared to 2.8 µM for wild-
type) (Table 9). We initially mutated this residue under the assumption that it could 
potentially act as a base catalyst. In fact, it was shown for GtfB (PDB code: 1IIR) that 
mutating the conserved D332 significantly reduced kcat 250-fold without affecting Km for 
UDP-glucose. The authors concluded that D332 is part of the catalytic apparatus and 
could act as a general base (118). However, it should be noted that no crystal structure of 
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GtfB bound to UDP-glucose is available. The role of the D/E-Q motif was further 
elucidated by Offen et al. demonstrating that D374 in VvGT1 (PDB code: 2C1Z) is 
involved in coordinating the glucose moiety of the sugar donor by hydrogen bonding to 
3-OH and 4-OH via the carboxyl group. The D374A mutation in VvGT1 also abolished 
the catalytic activity to non-detectable level, consistent with our IroB D304N mutant 
(122). The amino acid sequence of 2C1Z is included in the multiple sequence alignment 
shown in Figure 24, and it aligns very well in this region thus demonstrating that the 
residue D374 in 2C1Z is equivalent position as D304 in IroB. Based on this information, 
we conclude that D304 is involved in glucose orientation rather than acting as a base 
catalyst. Since the catalytic activity is absent or below detectable level in GtfB, VvGT1 
and IroB when D/E motif is altered, the exact positioning of the glucose moiety is 
apparently essential for inverting glycosyltransferases employing an SN2 mechanism.  
In summary, this result provides us with valuable information about the exact position of 
the glucose moiety, and therefore the location where the nucleophile attacks the anomeric 
carbon of glucose. This knowledge allows us to infer the position of the C5 of the ENT 
catechol during catalysis. 
 
6.3.3 E67 – a potential base catalyst 
The potential base catalyst E67 is localized in a region of IroB that is predicted to be a 
loop and is rather far away from the ENT binding site. Accordingly, the region of the 
ENT binding site is not conserved at all among homologs, suggesting that it is indeed a 
loop (see Figure 24). However, this region is clearly proximal to the ENT binding site 
and possibly contributes to the diversity of acceptor molecules that can be glycosylated. 
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Of all mutants we made with regard to potential base catalysts, this residue had the most 
severe impact on IroB catalysis, despite being far away from the active site in the model. 
After 1 h incubation only 30% MGE was detected, whereas most of ENT (70%) 
remained unprocessed. In comparison, IroB-CH6 (WT) completely converted ENT under 
the same conditions to DGE (88%) and TGE (12%) (see Table 7). At the same time, the 
E67A mutation had the least impact on protein fold and apparent binding affinity 
constant. E67A showed the same far-UV circular dichroism signature as wild-type IroB 
(Figure 30), the Tm was even slightly higher than with 39.6 °C as compared to 39.4 °C for 
wild-type (Table 8). The fluorescence spectroscopy analysis showed no disturbance of 
the tertiary structure – the spectra of wild-type and E67A were superimposable (Figure 
33). Furthermore, the apparent binding affinity constant KD’ was minimally affected (KD’ 
(E67A) = 4.8 µM compared to KD’ (WT) =2.8 µM) (Table 9). 
Since the E67A mutation does not result in any disturbance of the secondary or tertiary 
structure, and the affinity for ENT is not impaired, it provides further support that E67 is 
indeed located in a loop as predicted by our homology model. Since E67 is rather distant 
from the active site, we therefore assume that this loop might be mobile and possibly 
closes over ENT upon binding. The template structure for our homology model UrdGT2 
(PDB code 2P6P) possesses also a long, presumably mobile loop adjacent to the acceptor 
binding site (74). Regrettably, the three-dimensional structure of the C-
glycosyltransferase UrdGT2 was solved in the absence of glycosyl-donor and -acceptor 
molecules; however, this did not prevent the authors from suggesting a mechanism for 
the C-glycosylation of the acceptor molecule UWM6 (University of Wisconsin Madison 
compound no. 6). They proposed the presence of two base catalysts in the UrdGT2 active 
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site. Since only one was found in the rigid part of UrdGT2, they suggested that a mobile 
loop (62-72 or 219-228) closes over UWM6 upon binding so that the second base 
catalyst, namely E66, E71 or E224, can fulfil its function (74). Since E67 is similarly 
positioned in a mobile loop between residues 60-75 on IroB, it is possible that the region 
between residues 62-72 in UrdGT2 also contains important catalytic residues. Further 
support for this perception comes from a recent publication in which the authors 
rationally designed a C-glycosyltransferase from an O-glycosyltransferase using 
segments from UrdGT2 (64). Remarkably, they achieved the desired switch in activity 
and identified segment 52-62 to be responsible, however, they did not identify specific 
protein-ligand interactions. The C-glycosylating activity, though, was low compared to 
wild-type UrdGT2 leading to the conclusion that residues upstream of 62 are also 
important for catalysis. Our experiments with the UrdGT2 homolog IroB strongly support 
this hypothesis. 
 
6.3.4 Other residues 
In the course of this project several other variants were generated and their activity was 
tested. Among these are E60L, R64A, double mutant H65A/H66A, double mutant 
K71A/K72A, N81A, H134A, H138L and triple mutant H65A/H66A/H138L. All of them 
were tested for activity and most of them were on a similar level with wild-type as 
determined by our RP-HPLC assay. Activity was slightly affected in H134A and 
H65A/H66A. However, due to time limitations, these mutants were not fully 
characterized, especially H134A for which no biophysical data is available. The KD’ was 
not determined for any of them. 
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Since most of these residues are apparently not involved in catalysis we decided to focus 
on H134A and H65A/H66A. The double mutation H65A/H66A is located adjacent to 
E67 on the presumably mobile loop that closes over ENT upon binding. Biophysical 
characterization of this double mutant revealed no disturbance, neither of the secondary 
nor the tertiary structure as determined by far-UV circular dichroism, thermal 
denaturation and fluorescence spectroscopy. The impact on catalysis compared to E67 is 
moderate, and this variant is still capable of producing MGE (60%) and DGE (32%), 
consuming almost all substrate ENT. Given the position in the loop adjacent to the 
important residue E67, H65/H66 could polarize E67 or play a structural role and 
therefore enhance the catalytic function of E67. 
The residue H134 was, along with residue H138, among the most promising initial 
targets for base catalysts. Firstly, both histidine residues are positioned in the rigid part of 
the binding pocket close to the site of glycosylation, and secondly, in this region was the 
base catalyst Asp137 in UrdGT2 located (64, 74). None of them had an effect severe 
enough to be an essential catalytic residue. The variant H138L was fully active. However, 
an interesting pattern was observed in the RP-HPLC analysis of the supernatant of 
H134A (Table 7). The analysis shows the same relative abundance for ENT (8%) 
compared to double mutant H65A/H66A, however, the values for MGE (29%) and DGE 
(63%) are inverted compared to H65A/H66A. This was not observed previously; usually 
ENT is completely consumed when DGE is accumulated. This indicates that H134 could 
have a rate enhancing effect on catalysis. It should be noted, though, that this experiment 
was done only once and has to be reproduced before further hypotheses can be generated. 
Furthermore, the biophysical characterization (CD, fluorescence) of this variant is 
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missing, and therefore it cannot yet be excluded that the structural integrity was impaired 
by this mutation.      
 
6.3.5 Proposed mechanism for C-glycosylation based on results 
The authors who performed the first in vitro characterization of IroB proposed that a base 
catalyst in the active site of IroB deprotonates the 2-OH of the 2,3-DHB subunit of ENT, 
thus rendering C5 para to the 2-OH nucleophilic (see Section 1.6, Figure 11) (43). This 
nucleophile, then, attacks the electrophilic anomeric carbon of the glucose moiety of the 
donor molecule UDP-glucose resulting in the observed C-C bond. We extend this 
mechanistic hypothesis by two major points: (i) the deprotonation of the 2-OH is not 
essential, but is a rate-determining step, and (ii) we predict the existence of a second base 
catalyst that helps removing the hydrogen at the site of glycosylation after the 
glycosylation occurred to re-establish the aromatic system. 
To (i) we can offer several reason why deprotonation is not essential, but rate 
determining. The catechol subunit of ENT possesses two strongly activating hydroxyl 
substituents (124). Hydroxyl substituents on benzene rings are known to be ortho/para 
directing groups resulting from unshared pairs of electrons of the oxygen that can be 
donated in the ring system (125). Consequently, the resonance structures can be drawn as 










Figure 35: The catechol and its resonance contributor. On the left the most stable Lewis structure is 
shown followed by dipolar contributors (figure adapted from (125)). Position 1 is connected via an amide 









Since the site of glycosylation is para to 2-OH on C5, the 2-OH must therefore be the 
donating group. Because of this highly activating 2-OH substitution, the ring system is 
already much more nucleophilic in the para position and thus more reactive than a non- 
substituted benzene ring (125). An even more striking effect, though, is given by the 
ortho carbonyl group (of the amide linkage in ENT) of 2-OH of the 2,3-DHB subunit of 
ENT, which significantly lowers the pKa of the 2-OH group due to its electron with-
withdrawing effect, in addition to the delocalizing effect of the aromatic ring system 
(125). The pKa values for the non-substituted catechol are 9.25 and 13 for the first and 
second hydroxyl, respectively (126). However, upon ENT substitution, the catechol pKa 
values change to between 6.5 and 8 for the dissociation of the first hydroxyl group and 
11.5 for the second hydroxyl group (18). Therefore, under assay conditions at pH 7.5 the 
2-OH of the DHB subunit of ENT can be expected to be partially deprotonated, thus 
making a base catalyst non-essential, but possibly rate enhancing. The absence of this 
base catalyst should therefore not completely prevent glycosylation at C5. An appropriate 
base catalyst to carry out this function could be IroB E67, since we still observed some 
activity (the formation of MGE).  
This notion is further supported by the hydrophobic binding pocket in IroB predicted by 
our model, consisting of residues F84, F85, L10, L13 and L110. The site of glycosylation 
is C5, the hydrophobic hydrocarbon side of the catechol, whereas the hydroxyl groups of 
the catechol are hydrophilic and thus pointing away from these hydrophobic residues 
towards the solvent. There, the 2-OH is accessible to the predicted loop closing over ENT 
upon binding where E67 is located. Accordingly, the residue that accommodates the 
proton from C5 after glycosylation might be located in the rigid part of the binding 
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pocket. Interestingly in this context, Fischbach et al. did not observe any deuterium 
exchange at C5 of ENT in the presence of IroB and UDP, when trying to prove the 
existence of carbanion formation (43) and to explain why brominated ENT at position C5 
bound more tightly to IroB (82). This could indicate that C5 is indeed located in a 
hydrophobic binding pocket and therefore not accessible to the solvent, providing further 
support for our model-based hypotheses. 
With regard to point (ii), it is generally assumed that the aryl-C-glycosylation follows the 









Figure 36: Mechanism of an aromatic electrophilic substitution. During Friedel-Crafts alkylation the 
benzene ring is substituted with an acyl group (X = [R-(C=O)-]) (figure adapated from (124))  
 
In this mechanism the nucleophile attacks an electrophile under formation of a so-called 
σ-complex. The aromatic character is abrogated in the resulting σ-complex. However, the 
cation is stabilized by resonance contribution. In order to stabilize the carbocation and 
avoid loss of electrophile, the site of substitution must be deprotonated, and thus the 
aromatic system restored (124, 125). Accordingly, we predict the existence of another 
base catalyst in the active site of IroB, which abstracts a proton from the site of 
glycosylation to restore aromaticity after glycosylation has occurred. The existence of a 
second base catalyst was also predicted for the C-glycosyltransferase UrdGT2 for the 
same purpose (74) and was recently identified as S10 (64). Despite our efforts, we did not 
identify an appropriate base catalyst in IroB yet. However, IroB possesses a tyrosine at 
120 
 
position 11 - almost exactly the same position as the IroB homolog UrdGT2 (S10) - and 
is therefore likely the required residue for this function.  This is further supported by the 
conservation of this residue among homologs (Figure 24), where usually at this position a 
serine, tyrosine or histidine can be found, followed by a highly conserved glycine.  
Based on the results we can propose the mechanism for C-glycosylation of ENT as 





























coordination of glucose: D304
W264: stacking interaction with uridine
 
Figure 37: Proposed mechanism for the C-glycosylation of ENT.  
 
The phenolic character of the 2,3-DHB subunit is increased by (position 1) depronotation 
of the 2-OH by E67, which results in higher electron density at C5 para to the 2-OH 
group thus rendering this position nucleophilic. This position then attacks the anomeric 
carbon of the glucose moiety (position 2) in a SN2 displacement mechanism supported by 
the phosphate leaving group. Simultaneously, Y11 acts as an acid catalyst and donates a 








developing negative charge. The tyrosine then acting as a base catalyst and 
accommodates the proton of the site of glycosylation (position 3) to re-aromatize the 2,3-
DHB subunit of ENT (position 4).  
 
6.4 Summary and Future Work 
In the course of this work we expressed and purified the C-glycosyltransferase IroB to 
near-homogeneity (>85%). In addition, we established an activity assay that allowed us to 
detect conversion products MGE/DGE/TGE arising from IroB activity, and to quantitate, 
in a limited manner, relative amounts of product formation. We found that divalent metal 
ion (Mg
2+
) is needed for efficient catalysis, presumably to facilitate product release. We 
then produced a homology model of IroB that provided us with a structural framework to 
generate robust mechanistic hypotheses. We identified several residues that play an 
important role during catalysis; among these are D304, W264 and E67. Based on the 
information provided by our experimental data such as activity assay and biophysical 
characterizations, and in addition information given in the literature, we assume that 
W264 and D304 are likely involved in coordinating the nucleotide base and glucose 
moiety, respectively. The other residue that had a severe impact on catalysis was E67, 
which is an excellent candidate to act as a general base catalyst. It is predicted to be 
located on a mobile loop that could close over ENT upon binding. To confirm this 
prediction, we propose mutating position A61, G62 and A68 to prolines, thus introducing 
more rigidity into this loop. These mutations should immobilize the loop and 
significantly reduce activity, similar to what we observed for the E67A variant, if this 
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loop indeed closes over ENT upon binding. An interesting alternative could be the 
introduction of a Trp on the loop to follow closure and opening by a FRET-based assay. 
Despite our efforts we couldn’t find an appropriate second base catalyst that could 
accommodate the proton at the site of glycosylation. However, a very recent finding with 
the IroB C-glycosyltransferase homologue UrdGT2 suggests that Y11 in IroB is an 
excellent candidate to fulfil this function. This notion is further supported by the 
relatively high conservation of residues at this position among glycosyltransferases. We 
propose substituting Y11 by a phenylalanine to remove the proton donor/acceptor that 
may mediate acid/base function during catalysis in our proposed mechanism (Figure 37). 
 
Further issues that have to be addressed are the qualitative nature of our activity assay as 
well as the way the enzymatic reaction is terminated. Fischbach et al. were able to derive 
kinetic parameters such as kcat and Km (43). However, due to the unstable nature of ENT 
with a t1/2 = 30 min under physiological conditions (19) we observed breakdown of ENT 
during this incubation period. To address this problem, Fe
3+
 could be added to stabilize 
ENT (127). The addition of Fe
3+
, however, would also terminate the reaction since holo-
ENT is not a substrate for IroB; it could also lead to precipitation of IroB consistent with 
our previous observations. It is notable that ferric-ENT does not bind to reversed phase 
column and has to be acidified shortly before separation is performed to avoid breakdown 
of ENT. However they could be obtained, kinetic parameters would be useful in 
determining the catalytic efficiencies of the first, second and third glycosylation steps 
could be compared. For this purpose, the intermediate substrates MGE/DGE would have 
to be purified by preparative reversed phase chromatography, and then used as a substrate 
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in steady-state kinetic assays. In addition, the apparent equilibrium binding affinity 
constant can be determined for each substrate if they were available in a purified form. 
Therefore, we would gain more insight into why DGE is mostly found in supernatants of 
iroA harbouring strains, but not MGE/TGE. Lastly, our polyclonal anti-IroB antibody 
opens the gates to perform co-immunoprecipitation experiments to identify possible 
protein-protein interaction partner. An interesting candidate is EntF, since an IroB-EntF 
interaction could facilitate channelling of ENT directly to IroB to prevent it from being 
exported before glycosylation occurs, or to be partitioned into the E. coli inner membrane 
upon dissociation from EntF. Straightforward experiments such as co-
immunoprecipitation using Nissle 1917 (iron starved) lysate followed by 2D gel 
electrophoresis and MS analysis of resolved spots could identify potential IroB-
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